¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2022/8/19 ¤W¤È 11:21:50
²Ä 5483 ½g¦^À³
|
ÅÞ¿è«ä¦ÒÃD¡I º¥ý¤Þ¥Î 1. ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/15 ¤U¤È 12:48:18 ¼Ú¬w°Ï±ÂÅvµ{§Ç¥i¯à¤xû£°Ê¡A°t¦X9¤ë7-10¤é¦b¼Ú¬w¥Ö½§Âå¾Ç¨ó·|µoªí¤T½g½×¤å¡A¤~¯à¦b¸Ñª¼«á°¨¤Wñ¸p¡C 2. ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/17 ¤U¤È 12:13:49 Dupilumab ¤T´Á EASI75 Àø®Ä(2¶g¤@°w) (Àø®Ä®t²§=¹êÅç²Õ-¹ï·Ó²Õ, ¹êÅç²Õ/¹ï·Ó²Õ) Solo 1 51%(¹êÅç²Õ) VS 15%(¹ï·Ó²Õ)(51%-15%=36%, 51%/15%=3.4) Solo 2 44%(¹êÅç²Õ) VS 12%(¹ï·Ó²Õ)(44%-12%=32%, 44%/12%=3.7) ASLAN004 2b EASI75 Àø®Ä(2¶g¤@°w)---¹w¦ô 73%(¹êÅç²Õ) VS 15%(¹ï·Ó²Õ)(73%-15%=58%, 73%/15%=4.9) -----------------------------------------ÅÞ¿è«ä¦Ò----------------------------------------- ºî¤W¡A ¨È·à±d¦Û¤v·|¥h§ä¤jÃļt½Í±ÂÅv¡A§ä´X®a?3®a©Î5®a©Î¡K¡K ±µ¤U¨Ó A.¦b9/7~9/10¸q¤j§Q¦ÌÄõ½×¾Â«á¡A¦UÃļt¤ß¸Ì¦³©³¡A¬On³Q±ÂÅv©Î¨Ö¨È·à±d¤F¡C B.«á±ÁÙ¦³9/15ªº¯Ã¬ùR&D day C.¦~©³´Á¤¤³ø§i(9/26«eªÑ»ù¤W1¬ü¤¸³sÄò10¤Ñ´N¤£¥Î´¦ÅS´Á¤¤³ø§i¤F) D.112¦~3/4¤ë¥¿¦V¸Ñª¼ ¾ã¦XA.B.C.D. ©ú¦~3/4¤ë¸Ñª¼«á¡A¥u¦³¨È·à±d¦Û¤v§äªºÃļt¦³¿ìªk·í¤U°µ¨Mµ¦¡A ¬On³Q±ÂÅv©Î¨Ö¨È·à±d¤F¡C ¹ï«á¨Ó¤~ª¾¹DÅåÆv¸Ñª¼¼Æ¾Úªº¤jÃļt¤£¤½¥¡K¡K ¥u¯à´Á«Ý²{¶¥¬q¨È·à±d§äªº¼Ú¬w°Ï±ÂÅv¼t°Ó³£¬Oª¾¦W¤jÃļt¡C (²{¶¥¬q¤jÃļt·|²z§A³o¨S¨SµL»Dªº¤p¤½¥q)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/8/18 ¤W¤È 10:51:03
²Ä 5482 ½g¦^À³
|
«Øij¤½¥q ¤T´ÁÁ{§É ¼W¥[Dupilumab ¤@²ÕÁ{§É,¦¬Ó100¤H´N¨¬¤w¥´±ÑDupilumab. P=0.00015
EASI75 PK ¼ÒÀÀ
1.ASLAN004 73% VS Dupilumab 51% °²³]N=200:100 ,(100 ¦¬®×Ó¤¤¤ß)
x^2 14.31176384 P= 0.00015
«Øij¤½¥q ¤T´ÁÁ{§É ¼W¥[Dupilumab ¤@²ÕÁ{§É,¦¬Ó100¤H´N¨¬¤w¥´±ÑDupilumab. CIBINQO ¤fªAÃĤT´Á¦³PK Dupilumab,¦Ó«ÅºÙCIBINQOÀø®ÄÀu©óDupilumab. ¥i±¤CIBINQO¦³ÄY«°Æ§@¥Î,¦Ó³QFDA¦C¬°¥Íª«»s¾¯ªº«á½u虊.
------------------------------------------------------- EASI75 Àø®Ä PK---×1
¤@.Dupilumab ¤T´Á EASI75 Àø®Ä(2¶g¤@°w) (Àø®Ä®t²§=¹êÅç²Õ-¹ï·Ó²Õ, ¹êÅç²Õ/¹ï·Ó²Õ)
Solo 1 51%(¹êÅç²Õ) VS 15%(¹ï·Ó²Õ)(51%-15%=36%, 51%/15%=3.4) Solo 2 44%(¹êÅç²Õ) VS 12%(¹ï·Ó²Õ)(44%-12%=32%, 44%/12%=3.7)
¤G.Lebrikizumab ¤T´Á EASI75 Àø®Ä(2¶g¤@°w)
V 1 59%(¹êÅç²Õ) VS 16%(¹ï·Ó²Õ)(59%-16%=43%, 59%/16%=3.7) V 2 51%(¹êÅç²Õ) VS 18%%(¹ï·Ó²Õ)(51%-18%=33%, 51%/18%=2.8)---¦]MOA¬G,¤£Ã©w¤§Àø®Ä
¤T.ASLAN004 2b EASI75 Àø®Ä(2¶g¤@°w)---¹w¦ô
73%(¹êÅç²Õ) VS 15%(¹ï·Ó²Õ)(73%-15%=58%, 73%/15%=4.9) |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2022/8/17 ¤U¤È 02:18:47
²Ä 5481 ½g¦^À³
|
ir.aslanpharma.com/static-files/1c525489-d209-42c4-af7e-992f23c4251c
²³ø²Ä16¶004¹ï©óIL-13R£\1ªºµ²¦X¤O¤j©óIL-13¨üÅé¬ù60¿¡A³o¼Ëªº¯SÂI¬O¥i¯àĹ¹L§ù¥²ª¢ªº§Q¾¹¡AY¥H¤U¨â²Õ¸ÕÅç¯à§e²{ªvÀøªº²Îp·N¸q¨Ã¦bEASIĹ¹L¦Ñ§ù¡A´N¯à·íKing of A.DªvÀø~~~´Á«Ý2B´Á¤¤¼Æ¾Ú¤Î¸Ñª¼«á³o¨â²Õ¸ÕÅ窺¤ÀªR~~~¥[ªoªü·à
Experimental-3: ASLAN004 400 mg every four weeks (q4w) ASLAN004 400 mg q4w - loading doses at Baseline, Week 1 and Week 2, followed by regular doses of 400 mg or alternating placebo (q2W) to Week 14.
Experimental-4: ASLAN004 600 mg q4w ASLAN004 600 mg q4w - loading doses at Baseline, Week 1 and Week 2, followed by regular doses of 600 mg ASLAN004, alternating with placebo dose equivalents, q2W from Week 4 to Week 14. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/8/17 ¤U¤È 12:13:49
²Ä 5480 ½g¦^À³
|
EASI75 Àø®Ä PK---×1
¤@.Dupilumab ¤T´Á EASI75 Àø®Ä(2¶g¤@°w) (Àø®Ä®t²§=¹êÅç²Õ-¹ï·Ó²Õ, ¹êÅç²Õ/¹ï·Ó²Õ)
Solo 1 51%(¹êÅç²Õ) VS 15%(¹ï·Ó²Õ)(51%-15%=36%, 51%/15%=3.4) Solo 2 44%(¹êÅç²Õ) VS 12%(¹ï·Ó²Õ)(44%-12%=32%, 44%/12%=3.7)
¤G.Lebrikizumab ¤T´Á EASI75 Àø®Ä(2¶g¤@°w)
V 1 59%(¹êÅç²Õ) VS 16%(¹ï·Ó²Õ)(59%-16%=43%, 59%/16%=3.7) V 2 51%(¹êÅç²Õ) VS 18%%(¹ï·Ó²Õ)(51%-18%=33%, 51%/18%=2.8)---¦]MOA¬G,¤£Ã©w¤§Àø®Ä
¤T.ASLAN004 2b EASI75 Àø®Ä(2¶g¤@°w)---¹w¦ô
73%(¹êÅç²Õ) VS 15%(¹ï·Ó²Õ)(73%-15%=58%, 73%/15%=4.9) |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/8/17 ¤U¤È 12:05:19
²Ä 5479 ½g¦^À³
|
EASI75 Àø®Ä PK
¤@.Dupilumab ¤T´Á EASI75 Àø®Ä(2¶g¤@°w) (Àø®Ä®t²§=¹êÅç²Õ-¹ï·Ó²Õ, ¹êÅç²Õ/¹ï·Ó²Õ)
Solo 1 51%(¹êÅç²Õ) VS 15%(¹ï·Ó²Õ)(51%-15%=36%, 51%/15%=3.4) Solo 2 44%(¹êÅç²Õ) VS 12%(¹ï·Ó²Õ)(44%-12%=32%, 44%/12%=3.7)
¤G.Lebrikizumab ¤T´Á EASI75 Àø®Ä(2¶g¤@°w)
V 1 59%(¹êÅç²Õ) VS 16%(¹ï·Ó²Õ)(59%-16%=43%, 59%/16%=3.7) V 2 51%(¹êÅç²Õ) VS 19%%(¹ï·Ó²Õ)(51%-19%=32%, 51%/19%=2.7)---¦]MOA¬G,¤£Ã©w¤§Àø®Ä
¤G.ASLAN004 2b EASI75 Àø®Ä(2¶g¤@°w)---¹w¦ô
73%(¹êÅç²Õ) VS 15%(¹ï·Ó²Õ)(73%-15%=58%, 73%/15%=4.9)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/8/17 ¤W¤È 09:06:11
²Ä 5478 ½g¦^À³
|
ASLAN004 2b EASI75Àø®Ä ³]p¦ô:
1B EASI75 Àø®Äì³]p¦ô:
= A²Õ(°ò½u/¤¤µý=EASI31):11¤H/16¤H=69% + B²Õ(°ò½u/»´¯gEASI=19): 5¤H/6¤H=83%--)
A²Õ+B²Õ=¦Xp16/22=73%
---¤£±M·~ªº¦¬¤J«D¶Ç²ÎAD , 6¦ì¹êÅç²Õ±wªÌ+3¦ì¹ï·Ó²Õ, ¨Ï±o¸Ó²Õ6¦ì¹êÅç²Õ±wªÌ EASI75 Àø®Ä=0%.
¨Ï±oITT¤ÀªR EASI75 =¹êÅç²Õ(11+0)/22=50% VS ¹ï·Ó²Õ13% ---------------------------------------
2022¦~6¤ë7¤é ASLN CEO «Å§i: 2bÁ{§É¿z¿ï®É±N¥ý±Æ°£«D¶Ç²ÎAD±wªÌn©M Dupilumab ¤T´ÁÁ{§É¤@¼Ëªº±wªÌ²Õ¦¨µ²ºc(¥i¯à¥ý±Æ°£«D¶Ç²ÎAD±wªÌ,§CEASI/§CIgE/§CTRAC²Õ¥u¦³0%~3%ªº¾÷²v).
¦]¦¹2023¦~ASLAN004 AD 2b ¸Ñª¼, Y°ò½u¥§¡EASI27~30¤§³]p©Û¶Ò(¦PASLAN004 1b/¦PLebrikizumab 2b)
EASI75 ªº¥Ø¼ÐÀø®Ä¬ù73% VS ¹ï·Ó²Õ15%.(¹êÅç²ÕÀø®ÄÀu¹ï·Ó²Õ 73%-15%=58%, 73%/15%=4.9¿)
Lebrikizumab 2b, EASI75=60% VS 24%(¹ï·Ó²Õ), (¹êÅç²ÕÀø®ÄÀu¹ï·Ó²Õ 60%-24%=36%, 60%/24%=2.5¿)
Dupilumab ¤T´Á¹êÅç²Õ §CTRAC²Õ(°ò½uEASI25), Àø®Ä¥§¡EASI°´T77%(©Û¶Ò¤H¼Æ¤ñ1/3) ¤¤TRAC²Õ(°ò½uEASI31), Àø®Ä¥§¡EASI°´T67%(©Û¶Ò¤H¼Æ¤ñ1/3) °ªTRAC²Õ(°ò½uEASI41), Àø®Ä¥§¡EASI°´T66%(©Û¶Ò¤H¼Æ¤ñ1/3) ------------------------------------------ ¥§¡ (°ò½uEASI31),Àø®Ä¥§¡EASI°´T70%
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/8/17 ¤W¤È 07:26:40
²Ä 5477 ½g¦^À³
|
www.sec.gov/edgar/search/?r=el#/q=Dermira
Derm¤½¥q(Lebrikizmab),2020.2.10
³Q§¨Ó11»õ¬ü¤¸¨ÖÁʪºµû¦ô³ø§i¡C
¦ôp¥X¨C¦~ªº¦¬¤J¡B¦¨¥»¡B¬Õ¾l¡B²{ª÷¬y¤J«á¡A
¦A§é现ªº¦ô»ùªk¡C ¥t°Ñ¦ÒªÑ²¼¥«»ù¡A¤À§é®vªº¥Ø¼Ð»ù¡A¥«³õ¨ÖÁÊ»ù¡A ȱo¦U¦ì¤j¤j²`¤J¬ã¨s¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³v®ö«È10146323 |
µoªí®É¶¡:2022/8/16 ¤U¤È 04:22:37
²Ä 5476 ½g¦^À³
|
Large investors have recently bought and sold shares of the company. Waterfront Wealth Inc. acquired a new position in shares of ASLAN Pharmaceuticals in the 4th quarter valued at $302,000. Millennium Management LLC boosted its position in shares of ASLAN Pharmaceuticals by 2.8% in the 2nd quarter. Millennium Management LLC now owns 1,613,113 shares of the company¡¦s stock valued at $804,000 after purchasing an additional 43,949 shares during the period. Renaissance Technologies LLC lifted its stake in ASLAN Pharmaceuticals by 574.1% in the 2nd quarter. Renaissance Technologies LLC now owns 475,896 shares of the company¡¦s stock worth $236,000 after acquiring an additional 405,296 shares in the last quarter. Bank of America Corp DE lifted its stake in ASLAN Pharmaceuticals by 34.4% in the 1st quarter. Bank of America Corp DE now owns 259,722 shares of the company¡¦s stock worth $233,000 after acquiring an additional 66,544 shares in the last quarter. Finally, GSA Capital Partners LLP purchased a new stake in shares of ASLAN Pharmaceuticals during the 4th quarter worth about $89,000. Institutional investors own 38.65% of the company¡¦s stock. ¤j«¬§ë¸êªÌ³Ìªñ¶R½æ¤F¸Ó¤½¥qªºªÑ²¼¡C ¤ô©¤°]´I¤½¥q¦b²Ä¥|©u«×¦¬ÁʤF»ùÈ30.2¸U¬ü¤¸ªºªü´µÄõ»sÃĤ½¥qªº·sªÑ²¼¡C ¤dÁHºÞ²z¤½¥q¦b²Ä¤G©u«×±N¨ä¦bªü´µÄõ»sÃĤ½¥qªºªÑ²¼ÀY¤o¼W¥[¤F2.8%¡C Millennium Management LLC²{¦b¾Ö¦³1,613,113ªÑ¸Ó¤½¥qªºªÑ²¼¡A»ùÈ804,000¬ü¤¸¡A¦b¦¹´Á¶¡¤SÁʶR¤F43,949ªÑ¡C ´_¿³¬ì§Þ¦³³d¥ô¤½¥q¦b²Ä¤G©u«×¼W«ù¤F574.1%ªºªü´µÄõ»sÃĪѥ÷¡C ´_¿³¬ì§Þ¦³³d¥ô¤½¥q¦b¤WÓ©u«×¼W«ù¤F405,296ªÑ«á¡A²{¦b¾Ö¦³475,896ªÑ¸Ó¤½¥qªÑ²¼¡A»ùÈ23.6¸U¬ü¤¸¡C ²Ä¤@©u«×¡A¬ü°ê»È¦æ(Bank Of America Corp DE)¼W«ù¤Fªü´µÄõ»sÃĤ½¥q34.4%ªºªÑ¥÷¡C¬ü°ê»È¦æDE¥Ø«e«ù¦³259,722ªÑ¸Ó¤½¥qªÑ²¼¡A»ùÈ23.3¸U¬ü¤¸¡A¦¹«e¸Ó¤½¥q¦b¤W¤@©u«×¼W«ù¤F66,544ªÑ¡C³Ì«á¡AGSA Capital Partners LLP¦b²Ä¥|©u«×ÁʶR¤F»ùȬù8.9¸U¬ü¤¸ªºªü´µÄõ»sÃĤ½¥qªº·sªÑ¥÷¡C¾÷ºc§ë¸êªÌ«ù¦³¸Ó¤½¥q38.65%ªºªÑ¥÷¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/8/16 ¤U¤È 03:52:38
²Ä 5475 ½g¦^À³
|
¥¼¨Óý³Ý¤ÎEOE¡K¡KAD¥H¥~ªºASLAN004¾AÀ³¯gªº±ÂÅv¡C
¥i¥H参¦Ò¥H¤ULebrikizumab
2.2017/08/08 ±qAD¤G´ÁÁ{§É¶}©l°µ°_ (2019/10 ¤T´ÁÁ{§É¶}©l) Dermira¦Vù¤óROCHE ,ÁʶR Lebrikizumab¥þ²yAD¶}µoÅv«eª÷8000¸U¬ü¤¸¡A2018¦~¦A¤ä¥I5500¸U¬ü¤¸¡C ±Ò°Ê²Ä¤@Ó3´Á¤§«e¤ä¥I4000¸U¬ü¤¸¡A¦b¬Y¨Ç¦a°Ï¨ú±oÃÄÃÒ©Mº¦¸°Ó·~¾P°â¨ã¦³¨½µ{¸O·N¸q®É¤ä¥I2.1»õ¬ü¤¸¡A°£¶¡½è©ÊªÍ¯f¥H¥~ªº¾AÀ³¯gªº²b¾P°âÃB¹F¬Y¨Ç»ùȳ̰ª¹F¨ì10.25»õ¬ü¤¸,¦Xp¬ù14»õ¬ü¤¸,¥[¾P°â¤À¼í<= 10%. Áô§t28»õ¬ü¤¸³Ì°ª¾P°âÃB. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2022/8/16 ¤U¤È 03:30:39
²Ä 5474 ½g¦^À³
|
¨ä¹êTang Capital¤w¸g¬O³Ì¤jĹ®a¤F¡C¡C¡C ASLN³Ì¤jªÑªFTang Capital²Ä¤G©u¦A¶R¶i2268¤dªÑADR¡AÁ`«ùªÑ¨Ó¨ì5555¤dªÑADR,«ùªÑ约8%.(¥h¦~9¤ë1b¸Ñª¼«á¶}©l¶R¶i¡A¥§¡¦¨¥»1.36¬ü¤¸/ªÑ¡C
°²³]Tang Capital¦A¶R¶i5555¤dªÑADR(ªÑ»ù5¤¸)«ùªÑ¹F¨ì约16% Á`¥§¡¦¨¥»¤]¤~3.18¤¸¡A¦^¨ì¥h¦~9¤ë°_¶^ÂI¦Ó¤w¡C ¦ý«ùªÑ16%¡A¦b¨È·à±d¸gÀç¹Î¶¤¸Ì±¬O§_Á¿¸Ü¥i¥H¤jÁn¤F¡C¡C¡C¡C
»¡¤£©w¤§«á¨È·à±dn³Q¨ÖÁÊ¡A±onTang Capital¦P·N¡A¤~ºâ¼Æ¡C¡C¡C¡C¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/8/16 ¤U¤È 03:17:12
²Ä 5473 ½g¦^À³
|
¼Ú°Ï±ÂÅv¤Î¸êª÷ª¬ªp¸Õºâ:¡K¡K×1
¨Ì¾ÚLebrikizmab ¼Ú°Ï±ÂÅv Almirall ¦X约 ¡K¡KCEO«ÅºÙ欧¬w区AD³Ì°ª¥i¾P5»õ¬ü¤¸¡C
®ÚÕu该协议¡AAlmirall将对Dermira©Óü®¥H¤U¥I´Úúå务¡C
(1)3,000ÉE¬ü¤¸ªº´Á权费¡A¦b¥Í®Ä¤é´Á¦Z¼w¦Ì©Ô¥æ¥I该ª÷额ªº发²¼¦Z¤Q¡]10¡^个¤u§@¤é内¤ä¥I¡C
(1.1)¦pªGAlmirall¦b¦¬¨ì数Õu¥]©M开发计¦E¦Zªº45¤Ñ内¦æ¨Ï¨ä选择权¥H获±o许¥i证¡A则应¤ä¥I5,000ÉE¬ü¤¸ªº选择权¦æ¨Ï费¡A该费¥Î应¦bDermira¦b选择权¦æ¨Ï¦Z¥æ¥I该ª÷额ªº发²¼¦Z¤Q¡]10¡^个¤u§@¤é内¤ä¥I¡C
¤T´Á«e¥i¨ú±o8¤d¸U¬ü¤¸.
¨Ì¥Ø«eAD±ÂÅv¦æ±¡ASLAN004¥i¯ànLebrikizmab*3¿. ----(2019/02 Dupilumab ³Ì°ª¾P°â¦ô50»õ¬ü¤¸, 2022¦~Dupilumab ³Ì°ª¾P°â¦ô140»õ¬ü¤¸,2022¦~¦ô¥i¹F80»õ¾P°â)
AD¤T´Á«e¥i¨ú±o8¤d¸U¬ü¤¸*3=2.4»õ¬ü¤¸. ¦©°£¤ä¥ICSL 3000¸U¬ü¤¸,¤Î2023¦~¦ô6000¸U¬ü¤¸ªºÁ{§ÉºÞ¾P. 2023¦~ªºASLN µ|«eÀç¾l¦ô¥i¦³1.5»õ¬ü¤¸.¡K¡KC
================================= (2)¼w¦Ì©ÔûD动¬Y¨Ç3´Á临§É¬ã¨s¡]¨C项§¡为 3´Á试验¡^¡A¥i额¥~获±o3000ÉE¬ü¤¸¡A¨C项试验¦b达¨ì该¨½µ{¸O¦Z¤G¤Q¤¡]25¡^¤Ñ内¤ä¥I¡C
(3)Almirall实现¬Y¨Ç监ºÞ¨½µ{¸O¦Z¡A¥i额¥~获±o4,000ÉE¬ü¤¸¡A¨C笔´Ú项§¡应¦b实现该¨½µ{¸O¦Z¼w¦Ì©Ô¥æ¥I发²¼¦Z¤G¤Q¤(25)¤Ñ内¤ä¥I¡C
(4)¦b欧·ùº¦¸°Ó业¤Æ销°âlebrikizumab¦Z¡A获±o4500ÉE¬ü¤¸ªº¦¬¤J¡C
¥H¤W1.15»õ¬ü¤¸ *3=3.45»õ¬ü¤¸----ASLN 欧·ùº¦¸°Ó业¤Æ销°âASLAN004 ---¦©°£¤ä¥ICSL 9250¤d¸U ---2.5250»õ¬ü¤¸ ³Ñ¾l.-----A
--3´ÁADÁ{§É¶O¥Î¬ù4»õ¬ü¤¸+3¦~ºÞ¾P5000¸U+¨ä¥L¤G´ÁASLN004/ASLNA003¦ô1.5»õ¬ü¤¸.=¦Xp6»õ¬ü¤¸----B
B-A-C=2.0»õ¬ü¤¸¯Ê¤f,©ú¦~¸Ñª¼«á¤½¶}¥«³õ¶Ò¸ê©Î¨p¶Ò.
¥H¤W¬°Ó¤H¦ôºâ2024/2025/2026¦~ªºASLN¸êª÷¶i¥X.
±ÂÅvª÷ªº¤j¤p©M¶Ò资³W¼Ò¤j¤p¬ÛÃö¡C
¥H¤W¶È¹ïAD¡A¨ä¥L¾AÀ³¯g¦û¬ùAD¥«³õªº80%¡A¦ý±N¥u¶i¤J¤G´Á ý³Ý¡AEOE¡A³o¤G项¦ôp·|¥ý°µ¡A9¤ë15¤éR&D day ´Nª¾¹D¤F¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/8/16 ¤W¤È 10:49:02
²Ä 5472 ½g¦^À³
|
¼Ú°Ï±ÂÅv¤Î¸êª÷ª¬ªp¸Õºâ:
¨Ì¾ÚLebrikizmab ¼Ú°Ï±ÂÅv Almirall ¦X约 ¡K¡KCEO«ÅºÙ欧¬w区AD³Ì°ª¥i¾P5»õ¬ü¤¸¡C
®ÚÕu该协议¡AAlmirall将对Dermira©Óü®¥H¤U¥I´Úúå务¡C
(1)3,000ÉE¬ü¤¸ªº´Á权费¡A¦b¥Í®Ä¤é´Á¦Z¼w¦Ì©Ô¥æ¥I该ª÷额ªº发²¼¦Z¤Q¡]10¡^个¤u§@¤é内¤ä¥I¡C
(1.1)¦pªGAlmirall¦b¦¬¨ì数Õu¥]©M开发计¦E¦Zªº45¤Ñ内¦æ¨Ï¨ä选择权¥H获±o许¥i证¡A则应¤ä¥I5,000ÉE¬ü¤¸ªº选择权¦æ¨Ï费¡A该费¥Î应¦bDermira¦b选择权¦æ¨Ï¦Z¥æ¥I该ª÷额ªº发²¼¦Z¤Q¡]10¡^个¤u§@¤é内¤ä¥I¡C
¤T´Á«e¥i¨ú±o8¤d¸U¬ü¤¸.
¨Ì¥Ø«eAD±ÂÅv¦æ±¡ASLAN004¥i¯ànLebrikizmab*3¿. ----(2019/02 Dupilumab ³Ì°ª¾P°â¦ô50»õ¬ü¤¸, 2022¦~Dupilumab ³Ì°ª¾P°â¦ô140»õ¬ü¤¸,2022¦~¦ô¥i¹F80»õ¾P°â)
AD¤T´Á«e¥i¨ú±o8¤d¸U¬ü¤¸*3=2.4»õ¬ü¤¸. ¦©°£¤ä¥ICSL 3000¸U¬ü¤¸,¤Î2023¦~¦ô6000¸U¬ü¤¸ªºÁ{§ÉºÞ¾P. 2023¦~ªºASLN µ|«eÀç¾l¦ô¥i¦³1.5»õ¬ü¤¸.
================================= (2)¼w¦Ì©ÔûD动¬Y¨Ç3´Á临§É¬ã¨s¡]¨C项§¡为 3´Á试验¡^¡A¥i额¥~获±o3000ÉE¬ü¤¸¡A¨C项试验¦b达¨ì该¨½µ{¸O¦Z¤G¤Q¤¡]25¡^¤Ñ内¤ä¥I¡C
(3)Almirall实现¬Y¨Ç监ºÞ¨½µ{¸O¦Z¡A¥i额¥~获±o4,000ÉE¬ü¤¸¡A¨C笔´Ú项§¡应¦b实现该¨½µ{¸O¦Z¼w¦Ì©Ô¥æ¥I发²¼¦Z¤G¤Q¤(25)¤Ñ内¤ä¥I¡C
(4)¦b欧·ùº¦¸°Ó业¤Æ销°âlebrikizumab¦Z¡A获±o4500ÉE¬ü¤¸ªº¦¬¤J¡C
¥H¤W1.15»õ¬ü¤¸ *3=3.45»õ¬ü¤¸----ASLN 欧·ùº¦¸°Ó业¤Æ销°âASLAN004 ---¦©°£¤ä¥ICSL 9250¤d¸U ---2.5250»õ¬ü¤¸ ³Ñ¾l.-----A
--3´ÁADÁ{§É¶O¥Î¬ù4»õ¬ü¤¸+3¦~ºÞ¾P5000¸U+¨ä¥L¤G´ÁASLN004/ASLNA003¦ô1.5»õ¬ü¤¸.=¦Xp6»õ¬ü¤¸----B
B-A=3.5»õ¬ü¤¸¯Ê¤f,©ú¦~¸Ñª¼«á¤½¶}¥«³õ¶Ò¸ê©Î¨p¶Ò.
¥H¤W¬°Ó¤H¦ôºâ2024/2025/2026¦~ªºASLN¸êª÷¶i¥X.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2022/8/16 ¤W¤È 10:13:03
²Ä 5471 ½g¦^À³
|
ÕY¸Ñª¼«á¨ä¹êÅç²Õ3¡A¯à¦³°ª©ó§ù¥²ª¢ªºÀø®Ä¤Î§C°Æ§@¥Î¡A¬Û«H¥«È·|¤ñ10»õ¬ü¤¸°ª¤W¤@¿¤£¤î~~~¥[ªoªü·à
Experimental 3: ASLAN004 400 mg every four weeks (q4w) ASLAN004 400 mg q4w - loading doses at Baseline, Week 1 and Week 2, followed by regular doses of 400 mg or alternating placebo (q2W) to Week 14. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/8/16 ¤W¤È 07:35:35
²Ä 5470 ½g¦^À³
|
©ú¦~3/4¤ë¸Ñª¼¦¨¥\¡I
Y¼Æ¾Ú¶W¶VDupilumab 3´Á¨C¤G¶g¤@°w¡A40% EASI75 69%(ASLAN004) vs 48%(dupilumab)
69%/48%=142%
Y©M¨é°Ó½Í¦nªº¥]¾P»ù6.4¬ü¤¸/ªÑ(¥«»ù8¬ü¤¸)
Y§A¬OTang Capital CEO ,
§A·|¦b¸Ñª¼«e¥«³õ§C»ù¦¬ÁÊ ASLN¡HÁÙ¬O参¥[¨p¶Ò¡H
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/8/16 ¤W¤È 04:44:00
²Ä 5469 ½g¦^À³
|
whalewisdom.com/stock/asln
ASLN³Ì¤jªÑªFTang Capital²Ä¤G©u¦A¶R¶i2268¤dªÑADR¡AÁ`«ùªÑ¨Ó¨ì5555¤dªÑADR,«ùªÑ约8%.(¥h¦~9¤ë1b¸Ñª¼«á¶}©l¶R¶i¡A¥§¡¦¨¥»1.36¬ü¤¸/ªÑ¡C
·s¥[©Y²H°¨¿ü«ùªÑ¨S°Ê¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/8/15 ¤U¤È 07:33:15
²Ä 5468 ½g¦^À³
|
www.nejm.org/doi/full/10.1056/nejmoa1610020
Dupilumab ¹Ï¤G¡A¤T´ÁÁ{§É¼Æ¾Ú¡CÁͶչÏ
¤j¬ù12¶gªvÀø¥i±µªñ100%EASIªº¥§¡Àø®Ä¡C
¤j¬ù8¶gªvÀø¥i¹F90%ªºEASI¤Îpruritus NRS ªº¥§¡Àø®Ä¡C¡]¥iª¾EASI75ªº¥¼¸Ñª¼ªº¤ñ¨Ò¡^
¤j¬ù4¶gªvÀø¥i¹F70%ªºEASIªº¥§¡Àø®Ä¡A¥§¡¥i°EASI50%¡C
5¤ë7¤é¶}36Ó¡]36/59=61%¡^¤¤¤ß¥[3Ó¤ë¡A¬ù¸g¦Ü¤Ö¤@Ó¤ëªvÀø¡A8¤ë7¤é¤j¬ù¥iª¾¬O§_¹F°EASI50¡AºÙ¦³¤ÏÀ³ªº¥¼¸Ñª¼ªº¤ñ¨Ò¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³v®ö«È10146323 |
µoªí®É¶¡:2022/8/15 ¤U¤È 07:09:14
²Ä 5467 ½g¦^À³
|
Aslan Pharmaceuticals Price Target Cut to $7.00/Share From $8.00 by HC Wainwright & Co. ªü´µÄõ»sÃĪº¥Ø¼Ð»ù³QHC Wainwright&Co.±q¨CªÑ8.00¬ü¤¸¤U½Õ¦Ü7.00¬ü¤¸¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³v®ö«È10146323 |
µoªí®É¶¡:2022/8/15 ¤U¤È 07:01:31
²Ä 5466 ½g¦^À³
|
Aslan Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co. HC Wainwright&Co.¹ïªü´µÄõ»sÃĤ½¥qºû«ù¡¨¶R¶i¡¨«Øij. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/8/15 ¤U¤È 01:42:16
²Ä 5465 ½g¦^À³
|
www.nejm.org/doi/full/10.1056/nejmoa1610020
Dupilumab ¹Ï¤G¡A¤T´ÁÁ{§É¼Æ¾Ú¡CÁͶչÏ
¤j¬ù8¶gªvÀø¥i¹F90%ªºEASI¤Îpruritus NRS ªºÀø®Ä¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/8/15 ¤U¤È 12:48:18
²Ä 5464 ½g¦^À³
|
¼Ú¬w°Ï±ÂÅvµ{§Ç¥i¯à¤xû£°Ê¡A°t¦X9¤ë7-10¤é¦b¼Ú¬w¥Ö½§Âå¾Ç¨ó·|µoªí¤T½g½×¤å¡A¤~¯à¦b¸Ñª¼«á°¨¤Wñ¸p¡C
³o¼Ë1.25»õ¬ü¤¸¡]3000¸U¬ü¤¸¤T´ÁÁ{§É¶}©l¤ä¥I¡A¨ä¥Lùµ{ª÷¡A¨úÃÒ«e¥I¡^¥I CSLªº´N¦³µÛ¸¨¤F¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2022/8/15 ¤U¤È 12:41:51
²Ä 5463 ½g¦^À³
|
100¤H(¦û1/3)¥¼¸Ñª¼ªº¼Æ¾Ú¡K.. ¨ä¹ê¤j·§¤w¸gª¾¹Dµ²ªG¤F¡K¡K¡K ªÑ»ù·|öt¡Aªí¥Ü¼Æ¾Ú¡K¡K¡K¡K
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/8/15 ¤U¤È 12:35:43
²Ä 5462 ½g¦^À³
|
Lebrikizumab 2b ¸Ñª¼¤é¤½¥¬¡G2019¦~2¤ë7¤é
¼Ú¬w±ÂÅv ÀH«á7¤é¤½¥¬¡C2¤ë14¤é
A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis
Study Design Go to sections Study Type : Interventional (Clinical Trial) Actual Enrollment : 280 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Investigator, Outcomes Assessor) Primary Purpose: Treatment Official Title: A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis Actual Study Start Date : January 30, 2018 Actual Primary Completion Date : February 7, 2019 Actual Study Completion Date : May 23, 2019
www.clinicaltrials.gov/ct2/show/NCT03443024
¤G¡B®Ú¾ÚLebrikiumab³Q±ÂÅvAlmirall ¦X约 ¡K¡KCEO«ÅºÙ欧¬w区AD³Ì°ª¥i¾P5»õ¬ü¤¸¡C ¡K¡K«eª÷+¶}µoùµ{ª÷1.98»õ¬ü¤¸+12.5»õ¬ü¤¸¡A³Ì°ª¾P°âùµ{ª÷(30»õ¬ü¤¸³Ì°ª¾P°â) +¾P°â¤À¼í10%-20%
±ÂÅvª÷1.98+2.1(5/30*12.5¡K¡K5»õ¬ü¤¸销°â°ò¦)¡A约4»õ¬ü¤¸¡C
4»õ¬ü¤¸/20%(欧¬w区)=20»õ¬ü¤¸¡K¡K¾ãÅéLebrikiumab±ÂÅvª÷AD»ùÈ¡K¡KB
Lebrikizumab ¼Ú¬w°Ï±ÂÅv¦X¬ù(2019/02) www.sec.gov/edgar/search/?r=el#/q=Dermira
ùµ{ª÷(1)3000+(1.1)5000+(2)3000+(3)4000+(4)4500=19,500(¸U¬ü¤¸) +(5)®ÚÕulebrikizumab¦b欧¬wªº¦~净销°â额达¨ì8600ÉE¬ü¤¸¦Ü30亿¬ü¤¸ªº¬Y¨Ç门槛¡A ¤ä¥I³Ì¦h12.5亿¬ü¤¸ªº´Ú项¡A¨C笔ýͦbªº¨½µ{¸O¦¡¥I´Ú约¥eÓì¥Î净销°â额门槛ªº7%¦Ü15%¡F¥H¤Î
¾P°â¤À¼í(6)°ò¤_欧¬wlebrikizumab¦~净销°â额¬Û应S围ªº层级¦Ê¤À¤ñS围ªº¯S许权¨Ï¥Î费¤ä¥I¡A¨ä¤¤²Ä¤@¦~净销°â额层级ªº¦Ê¤À¤ñ从§C两¦ì数开©l¡A³Ì°ª净销°â额层级ªº¦Ê¤À¤ñ¼W¥[¨ì§C¤G¤Q¦ì数¡C
®ÚÕu该协议¡AAlmirall将对Dermira©Óü®¥H¤U¥I´Úúå务¡C
(1)3,000ÉE¬ü¤¸ªº´Á权费¡A¦b¥Í®Ä¤é´Á¦Z¼w¦Ì©Ô¥æ¥I该ª÷额ªº发²¼¦Z¤Q¡]10¡^个¤u§@¤é内¤ä¥I¡C
(1.1)¦pªGAlmirall¦b¦¬¨ì数Õu¥]©M开发计¦E¦Zªº45¤Ñ内¦æ¨Ï¨ä选择权¥H获±o许¥i证¡A则应¤ä¥I5,000ÉE¬ü¤¸ªº选择权¦æ¨Ï费¡A该费¥Î应¦bDermira¦b选择权¦æ¨Ï¦Z¥æ¥I该ª÷额ªº发²¼¦Z¤Q¡]10¡^个¤u§@¤é内¤ä¥I¡C
(2)¼w¦Ì©ÔûD动¬Y¨Ç3´Á临§É¬ã¨s¡]¨C项§¡为 3´Á试验¡^¡A¥i额¥~获±o3000ÉE¬ü¤¸¡A¨C项试验¦b达¨ì该¨½µ{¸O¦Z¤G¤Q¤¡]25¡^¤Ñ内¤ä¥I¡C
(3)Almirall实现¬Y¨Ç监ºÞ¨½µ{¸O¦Z¡A¥i额¥~获±o4,000ÉE¬ü¤¸¡A¨C笔´Ú项§¡应¦b实现该¨½µ{¸O¦Z¼w¦Ì©Ô¥æ¥I发²¼¦Z¤G¤Q¤(25)¤Ñ内¤ä¥I¡C
(4)¦b欧·ùº¦¸°Ó业¤Æ销°âlebrikizumab¦Z¡A获±o4500ÉE¬ü¤¸ªº¦¬¤J¡C
(5)®ÚÕulebrikizumab¦b欧¬wªº¦~净销°â额达¨ì8600ÉE¬ü¤¸¦Ü30亿¬ü¤¸ªº¬Y¨Ç门槛¡A¤ä¥I³Ì¦h12.5亿¬ü¤¸ªº´Ú项¡A¨C笔ýͦbªº¨½µ{¸O¦¡¥I´Ú约¥eÓì¥Î净销°â额门槛ªº7%¦Ü15%¡F¥H¤Î
(6)°ò¤_欧¬wlebrikizumab¦~净销°â额¬Û应S围ªº层级¦Ê¤À¤ñS围ªº¯S许权¨Ï¥Î费¤ä¥I¡A¨ä¤¤²Ä¤@¦~净销°â额层级ªº¦Ê¤À¤ñ从§C两¦ì数开©l¡A³Ì°ª净销°â额层级ªº¦Ê¤À¤ñ¼W¦Ü20% |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2022/8/15 ¤U¤È 12:35:19
²Ä 5461 ½g¦^À³
|
¨ä¹ê 4¤ë19¤é¡A¤w¶}20Ó©Û¶Ò¤¤¤ß¡A °²³]¥Î2Ó¤ë¨Ó©Û¶Ò+¿z¿ï¡A ¥Î4Ó¤ëªvÀø¡A «h10¤ë¤¤¡A¤½¥q¤w¦³¬ù100¤H¥¼¸Ñª¼ªº¨C2¶g¼Æ¾Ú¡K..
(¶V¨ì¦~©³,¤º½u¥æ©ö¶V©úÅã) |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/8/15 ¤U¤È 12:22:15
²Ä 5460 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2022/8/15 ¤U¤È 12:19:01
²Ä 5459 ½g¦^À³
|
¤Þ¥Î¤Ñ©R¤jµoªí ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/5/7 ¤W¤È 04:51:41 ASLAN004 AD 2b Á{§É:(§ó·s) ¦¬®×¤¤¤ß¼W¥[¡A¬ü°ê¦A¼W16³B¡A¥þ²y²Öp36³B¡C
×¥¿¬° 5¤ë7¤é¡A¤w¶}36Ó©Û¶Ò¤¤¤ß¡A
°²³]¥Î2Ó¤ë¨Ó©Û¶Ò+¿z¿ï¡A
¥Î4Ó¤ëªvÀø¡A «h11¤ëªì,16¶gªvÀø§¹¦¨¡C36/59=61%¡C
12¤ëªì¸ê®Æ¦¬¶°§¹¦¨©M¤½§G(12¤ëªì¥H«á¥i¥H´¦ÅS´Á¤¤¼Æ¾Ú)¡A
°²³]¼Ú¬w10¤ë©³§¹¦¨©Û¶Ò¡C
59/59,2¤ë©³¡A§¹¦¨16¶g
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/8/15 ¤W¤È 10:04:12
²Ä 5458 ½g¦^À³
|
6¤ë24¤é¡A¤w¶}36Ó©Û¶Ò¤¤¤ß¡A
°²³]¥Î2Ó¤ë¨Ó©Û¶Ò+¿z¿ï¡A
¥Î4Ó¤ëªvÀø¡A «h12¤ë©³,16¶gªvÀø§¹¦¨¡C36/59=61%¡C¡C
1¤ë©³ 45/59=77%¡AªvÀø16¶g§¹¦¨¡A
°²³]¼Ú¬w10¤ë©³§¹¦¨©Û¶Ò¡C
59/59,2¤ë©³¡A§¹¦¨16¶g
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³v®ö«È10146323 |
µoªí®É¶¡:2022/8/14 ¤U¤È 05:32:05
²Ä 5457 ½g¦^À³
|
This is a summary of current recommendations for ASLAN Pharmaceuticals and Geron, as provided by MarketBeat.com. ³o¬OMarketBeat.com´£¨Ñªº¹ïAslan PharmPharmticals©MGeron¨â¤äªÑ²¼ªº·í«e«ØijºKn¡C
ASLAN Pharmaceuticals currently has a consensus target price of $5.50, indicating a potential upside of 548.58%. Geron has a consensus target price of $4.50, indicating a potential upside of 91.49%. Given ASLAN Pharmaceuticals¡¦ higher possible upside, analysts plainly believe ASLAN Pharmaceuticals is more favorable than Geron. ªü´µÄõ»sÃĥثeªº¦@Ãѥؼлù¬°5.5¬ü¤¸¡Aªí©ú¼ç¦b¤W¦æªÅ¶¡¬°548.58%¡CGeronªº´¶¹M¥Ø¼Ð»ù¬°4.50¬ü¤¸¡A ªí©ú¼ç¦b¤W¦æªÅ¶¡¬°91.49%¡C¦Ò¼{¨ìªü´µÄõ»sÃħ󦳥i¯à¤W¦æ¡A¤ÀªR®vÅãµM»{¬°ªü´µÄõ»sÃĤñGeron§ó¦³§Q¡C
ASLAN Pharmaceuticals has a beta of 1.91, indicating that its stock price is 91% more volatile than the S&P 500. Comparatively, Geron has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. ªü´µÄõ»sÃĪº¨©¶ð«Y¼Æ¬°1.91¡Aªí©ú¨äªÑ»ùªºªi°Ê©Ê¤ñ¼Ð·Ç´¶º¸500«ü¼Æ°ª¥X91%¡C ¬Û¤ñ¤§¤U¡AGeronªº¨©¶ð«Y¼Æ¬°0.94¡A³oªí©ú¨äªÑ»ùªºªi°Ê©Ê¤ñ¼Ð·Ç´¶º¸500«ü¼Æ§C6%¡C
ASLAN Pharmaceuticals has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. ªü´µÄõ»sÃĪº¦¬¤J©M¦¬¯q¤ñGeron§ó°ª¡C Geronªº¥«¬Õ²v§C©óAslan PharmPharmticals¡A ³oªí©ú¥¦¥Ø«e¬O¨â°¦ªÑ²¼¤¤§ót¾á±o°_ªº¤@°¦¡C
ASLAN Pharmaceuticals beats Geron on 8 of the 14 factors compared between the two stocks. ªü´µÄõ»sÃĦb¨â°¦ªÑ²¼¤ñ¸ûªº14Ó¦]¯À¤¤¦³8ÓÀ»±Ñ¤FGeron¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³v®ö«È10146323 |
µoªí®É¶¡:2022/8/14 ¤U¤È 05:19:01
²Ä 5456 ½g¦^À³
|
ì¨Ó¦p¦¹¡AÁÂÁ¸Ѵb¡I
Asln¥[ªo¡A§Æ±æ¤j®a³£¯à¦p¤Ñ©R¤jÁ¿ªº¡A¹J¨ì¦¹Ãø±o ªº¾÷¹J¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/8/14 ¤U¤È 02:51:41
²Ä 5455 ½g¦^À³
|
³v®ö«È¤j¡A
¤£¦p¹w´Á¡I
Ib´Á¥½EASI75 ¤ñ´Á¤¤³ø§iÀø®Ä°¤Ó¦h¡C
´Á¤¤³ø§i EASI75 ¬O69% vs 0% ´Á¥¼³ø§i EASI75 50% vs 13% |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³v®ö«È10146323 |
µoªí®É¶¡:2022/8/14 ¤U¤È 01:32:19
²Ä 5454 ½g¦^À³
|
2021¦~9¤ë27¤é¤½¥¬1b ªº8©P¼Æ¾Ú¡A ¬Ý°_¨Ó¤ñdupilumab16¶gªvÀøÁÙn¦n¡A «ç«oµo¥Í´d¼@¡H¹ê¦b¤£¸Ñ¡I
¤£¹L¤£ºÞ©ú¤Ñ¹L«á¦p¦ó¡A §Æ±æªÑ»ù´Â¤Wµo®i⋯ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/8/14 ¤W¤È 08:22:32
²Ä 5453 ½g¦^À³
|
²q测--×1 1.ASLAN
2021¦~3¤ë¤½¥¬ASLAN004 lb ´Á¤¤¼Æ¾Ú
EASI75 =69% vs 0% ªÑ»ù³Ì°ª5¬ü¤¸/ªÑ¡A
2021 3-5¤ë¨é°Ó¥Ø¼Ð»ù8-10¬ü¤¸/ªÑ¡C
2.2021¦~9¤ë27¤é¤½¥¬1b ¼Æ¾Ú
EASI 75 =50%(¹êÅç组) vs 13%(¹ï·Ó组) ¡K¡KDupilumab 48.5%vs13% (aslan004 8¶gªvÀøITT¤ÀªR/dupilumab16¶gªvÀøÀø®Ä)
1b Àø®Ä´Á¤¤¤Î´Á¥½®t²§¬°©Û¶Ò6¦ì(6/22=27%)ªº«D¶Ç²ÎAD¯f±w¡A¦Ó¥L̪ºEASI75=0%
ªÑ»ù³Ì§C 6¤ë¨Ó¨ì0.355¬ü¤¸/ªÑ
3.CEO ©ó2022¦~6¤ë7¤é¨é°Ó³X½Í¤¤´¦ÅS¡A±N¦b2bÁ{§É«e¡Aç°£10%-15%ªº«D¶Ç²ÎAD¯f±w¡C¥u¿ï¶Ç²ÎAD¯f±w¶i¤J¤UÁ{§É¡A±µªñDupilumab ªº¤T´Á¯f±w¤À°t¡C
ªÑ»ù2022¦~6¤ë7¤é0.38¬ü¤¸¡AÀH«á°_º¦¡A2Ó¦h¤ë«á¤µ¤Ñ¡Aº¦¦^0.85¬ü¤¸¡A¤jº¦120%¦h¡A ÀH2b©Û¶Ò²Ä¤@¦WÀ³¤w§¹¦¨16¶gªvÀø¡AÁö¥¼¸Ñª¼¡A¦ý¥i²M·¡¤F¸Ñ¨C2¶gªºÀø®Ä¶i®i¡C
²z½×¤W¥»ªiªÑ»ùÀ³©¹5¬ü¤¸¾aªñ¡A«Ý¸Ñª¼«e¤@Ó¤ë约©ú¦~¤¸¤ë©³¡A¦A¯}«e°ª¡C
Y2b¸Ñª¼«á¦p1b RITT ¤ÀªR¡A 2bITT ¤ÀªR 16¶gªvÀø«áÀø®Ä¥i¹FEASI75=69%/13%¡AªÑ»ù¤W10¬ü¤¸¥ç¦³¥i¯à¡A 2b¸Ñª¼«áºò±µ¼Ú¬w°Ï±ÂÅv¡A¥Ñ±ø¥ó´N¤j¬ù¥i¬Ý¥XASLAN004ªº¾ãÅ饫³õ»ùÈ¡C¼Ú°Ï¦û¬ù20%ªº¥þ²y¥«³õ»ùÈ¡C
¥H¤WÓ¤H²q´ú¡A¶È¨Ñ°Ñ¦Ò¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/8/14 ¤W¤È 07:47:40
²Ä 5452 ½g¦^À³
|
预测 1.ASLAN 2022¦~3¤ë¤½¥¬ASLAN004 lb ´Á¤¤¼Æ¾Ú
EASI75 =69% vs 0% ªÑ»ù³Ì°ª5¬ü¤¸/ªÑ¡A
¨é°Ó¥Ø¼Ð»ù8-10¬ü¤¸/ªÑ¡C
2.2022¦~9¤ë27¤é¤½¥¬1b ¼Æ¾Ú
EASI 75 =50%(¹êÅç组) vs 13%(¹ï·Ó组) ¡K¡KDupilumab 48.5%vs13% (aslan004 8¶gªvÀøITT¤ÀªR/dupilumab16¶gªvÀøÀø®Ä)
1b Àø®Ä´Á¤¤¤Î´Á¥½®t²§¬°©Û¶Ò6¦ì(6/22=27%)ªº«D¶Ç²ÎAD¯f±w¡A¦Ó¥L̪ºEASI75=0%
ªÑ»ù³Ì§C 6¤ë¨Ó¨ì0.355¬ü¤¸/ªÑ
3.CEO ©ó6¤ë7¤é¨é°Ó³X½Í¤¤´¦ÅS¡A±N¦b2bÁ{§É«e¡Aç°£10%-15%ªº«D¶Ç²ÎAD¯f±w¡C¥u¿ï¶Ç²ÎAD¯f±w¶i¤J¤UÁ{§É¡A±µªñDupilumab ªº¤T´Á¯f±w¤À°t¡C
ªÑ»ù6¤ë7¤é0.38¬ü¤¸¡AÀH«á°_º¦¡A2Ó¦h¤ë«á¤µ¤Ñ¡Aº¦¦^0.85¬ü¤¸¡A ÀH2b©Û¶Ò²Ä¤@¦WÀ³¤w§¹¦¨16¶gªvÀø¡AÁö¥¼¸Ñª¼¡A¦ý¥i²M·¡¤F¸Ñ¨C2¶gªºÀø®Ä¶i®i¡C
²z½×¤W¥»ªiªÑ»ùÀ³©¹5¬ü¤¸¾aªñ¡A«Ý¸Ñª¼«e¤@Ó¤ë约©ú¦~¤¸¤ë©³¡A¦A¯}«e°ª¡C
Y¸Ñª¼«á¦p1b RITT ¤ÀªR¡A 2bITT ¤ÀªR 16¶gªvÀø«áÀø®Ä¥i¹FEASI75=69%/13%¡AªÑ»ù¤W10¬ü¤¸¥ç¦³¥i¯à¡A ºò±µ¼Ú¬w°Ï±ÂÅv¡A¥Ñ±ø¥ó´N¤j¬ù¥i¬Ý¥XASLAN004ªº¾ãÅ饫³õ»ùÈ¡C¼Ú°Ï¦û¬ù20%ªº¥þ²y¥«³õ»ùÈ¡C
¥H¤WÓ¤H²q´ú¡A¶È¨Ñ°Ñ¦Ò¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2022/8/13 ¤W¤È 10:21:32
²Ä 5451 ½g¦^À³
|
½L«á¶R³æÁÙ¬O»á¦h ¤U¶gÄ~Äò§V¤O§ð¤W1¤¸ ¤j®a¥[ªo |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/8/13 ¤W¤È 08:41:00
²Ä 5450 ½g¦^À³
|
°ê¥~¤ÀªR®v¥Ø¼Ð»ù8¬ü¤¸/ªÑ¡A ¨Ì¾ÚºD©Ê¡A¥i¯à¦b©ú¦~3¤ë©Î4¤ë 2b¸Ñª¼¤é¨ì¹F¡C
«e´£ 004ªº2b Àø®ÄEASI75 69%(¹êÅç²Õ)/13%(¹ï·Ó组) IGA 0.1 54%(¹êÅç²Õ)/8%(¹ï·Ó²Õ)
Dupilumab ¤T´Á EASI75. 48.5% vs 13% IGA0.1 36% vs 8%
2b ²Ä¤@¦ì3¤ë¤¤¦¯¶}©lªvÀø¡A¤½¥q¤w¦³¥¼¸Ñª¼ªº¨C2¶g¼Æ¾Ú¡A
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2022/8/12 ¤U¤È 11:53:38
²Ä 5449 ½g¦^À³
|
¶q¯à¤]¾ãÓ¥X¨Ó ·Pı©ú¤ÑºÎ¿ô¤@¬Ý´N¶W¹L1¤¸¤F «e°}¤lÁÙ¦bW´oªÑ»ù«ç¤W1¤¸¡A¦p¤µ¦n¹³»´»´ÃPÃP´Nn¹F¨ì ¯u¬O¥@¨ÆÃø®Æ°Ú |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2022/8/12 ¤U¤È 11:49:53
²Ä 5448 ½g¦^À³
|
1¬ü¤¸¡ã3¬ü¤¸®M¨c¶q¤£¤j¡A£¸©Ô´N¹L¡A«ç»ò¤U¨Ó «ç»ò¤W¥h ´Nºâ©Ô¹L3¬ü¤¸¤]¤£n¶Ã½æ¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³v®ö«È10146323 |
µoªí®É¶¡:2022/8/12 ¤U¤È 10:09:42
²Ä 5447 ½g¦^À³
|
ASLN.usªÑ»ù«æ³t¤Wº¦5.80%¡CºI¦Üµo½Z¡A¸ÓªÑ³ø0.730¬ü¤¸/ªÑ¡A¦¨¥æ¶q1.3¸UªÑ¡A´«¤â²v0.02%¡A®¶´T2.75%¡C
³Ìªñªº°]³ø¼Æ¾ÚÅã¥Ü¡A¸ÓªÑ¹ê²{Àç·~¦¬¤J0.00¬ü¤¸¡A²b§Q¼í-12.94¦Ê¸U¬ü¤¸¡A¨CªÑ¦¬¯q-0.19¬ü¤¸¡A¤ò§Q0.00¬ü¤¸¡A¥«¬Õ²v-1.33¿¡C
¾÷ºcµû¯Å¤è±¡A¦b©Ò¦³2®a°Ñ»Pµû¯Åªº¾÷ºc¤¤¡A100%ªº¨é°Óµ¹¤©¶R¤J«Øij¡AµL¨é°Óµ¹¤©«ù¦³¡B½æ¥X«Øij¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2022/8/12 ¤U¤È 09:52:00
²Ä 5446 ½g¦^À³
|
¤½¥q¬£¦³¤ßÀ³¸Ó¶X³oªi§âªÑ»ù©Ô¨ì1¤¸¥H¤W ¬Û«H¤]·|Åý¥«³õ«H¤ß¤j¼W |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³v®ö«È10146323 |
µoªí®É¶¡:2022/8/12 ¤U¤È 09:48:47
²Ä 5445 ½g¦^À³
|
¤WÓ©u«×¡A¸Ó¤½¥q¨CªÑ¦¬¯q¤ñ¹w´Á§C¤F0.01¬ü¤¸¡Aµ²ªG²Ä¤G¤ÑªÑ»ù¤U¶^¤F3.91%¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³v®ö«È10146323 |
µoªí®É¶¡:2022/8/12 ¤U¤È 09:44:27
²Ä 5444 ½g¦^À³
|
Aslan Pharma¤½§Gªº¨CªÑ¦¬¯q¬°-0.19¬ü¤¸¡A°ª©ó¹w´Áªº-0.2¬ü¤¸¡A¶W¥X¹w´Á5.0%¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/8/12 ¤U¤È 07:30:15
²Ä 5443 ½g¦^À³
|
ASLN ¤½¥¬²Ä¤G©u©u³ø¤Î§ó·s¥¼¨Ó¨½µ{¸O
finance.yahoo.com/news/aslan-pharmaceuticals-reports-second-quarter-110000376.html
Anticipated upcoming milestones
Three abstracts with new data on biomarkers and patient reported outcome measures from the Phase 1b proof-of-concept trial of eblasakimab have been accepted for e-poster presentation at the 31st EADV Annual Congress held in person and virtually, from September 7 to 10, 2022, in Milan, Italy.
The Company will host a Research and Development (R&D) Day on September 15, 2022, with a hybrid in-person and virtual format. More information will be announced in the weeks ahead.
Topline data from the Phase 2b TREK-AD trial of eblasakimab is expected in the first half of 2023.
Second quarter 2022 financial highlights
Cash used in operating activities for the second quarter of 2022 was US$9.7 million compared to US$6.9 million in the same period in 2021.
Cash, cash equivalents and short-term investments as of June 30, 2022, were US$78.1 million.
预计§Y将¨ì来ªº¨½µ{¸O
¤T¥÷关¤_¥ì¥¬©Ô¦è单§Ü1b´Á·§©À验证试验ªº¥Íª«标§Óª«©M±wªÌ报§i结ªG«ü标ªº·s数ÕuºKn¤w³Q±µ¨ü¡A将¦b2022¦~9¤ë7¤é¦Ü10¤é¦b·N¤j§Q¦Ì兰举¦æªº²Ä31届EADV¦~«×¤j会¤W¥H电¤l®ü报ªº§Î¦¡®i¥Ü¡C
¤½¥q将¤_2022¦~9¤ë15¤é举办¤@个¬ã¨sÉO开发¡]R&D¡^¤é¡Aªö¥Î现场©M虚úQ²V¦Xªº§Î¦¡¡C§ó¦h«H®§将¦b¥¼来¤L©P内¤½¥¬¡C
eblasakimabªº2b´ÁTREK-AD试验ªºªì¨B数Õu预计将¦b2023¦~¤W¥b¦~¤½¥¬¡C
2022¦~²Ä¤G©u«×财务ºKn
2022¦~²Ä¤G©u«×¥Î¤_经营¬¡动ªº现ª÷为970ÉE¬ü¤¸¡A¦Ó2021¦~¦P´Á为690ÉE¬ü¤¸¡C
ºI¦Ü2022¦~6¤ë30¤é¡A现ª÷¡B现ª÷µ¥É²ª«©Mµu´Á§ë资为7810ÉE¬ü¤¸¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³v®ö«È10146323 |
µoªí®É¶¡:2022/8/11 ¤U¤È 11:05:07
²Ä 5442 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³v®ö«È10146323 |
µoªí®É¶¡:2022/8/11 ¤U¤È 07:37:32
²Ä 5441 ½g¦^À³
|
¸É¥R¤@¤U¤Ñ©R¤j¸ê®Æ
Eblasakimab¬O¤@ºØ¼ç¦bªº°w¹ïIL-13¨üÅ骺¤@¬y³æ§Ü¡A¨ã¦³´£¨Ñ®t²§¤Æªº¦w¥þ©Ê©M¦³®Ä©Ê¥H¤Î¯SÀ³©Ê¥Öª¢±wªÌ§ï¶iªº¾¯¶q¤è®×ªº¼ç¤O¡C2021¦~9¤ë¡Aªü´µÄõ«Å§G¤F1b´Á¦h¾¯¶q»¼¼W¾¯¶q¬ã¨sªº¿n·¥µ²ªG¡A¸Ó¬ã¨s½T¥ß¤FASLAN004ªº·§©ÀÅçÃÒ¡A¨Ã¤ä«ù¨ä§@¬°AD·sÀøªkªº¼ç¤O¡C2022¦~1¤ë¡Aªü´µÄõ±Ò°Ê¤FTrek-AD 2b´Á¸ÕÅç¡A¥Hµû¦ôeblasakimab¦b¤¤««×AD±wªÌ¤¤ªº¦w¥þ©Ê©M¦³®Ä©Ê¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/8/11 ¤U¤È 07:09:24
²Ä 5440 ½g¦^À³
|
MENLO PARK, Calif. and SINGAPORE, Aug. 11, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that three abstracts, showcasing new findings related to eblasakimab, will be displayed as e-posters throughout the 31st European Academy of Dermatology and Venereology (EADV) Congress, to be held in-person and virtually from September 7 to 10, 2022, in Milan, Italy.
31st European Academy of Dermatology and Venereology Congress e-poster details Poster 1: Eblasakimab improves multiple disease measures in adult patients with moderate-to-severe atopic dermatitis in a randomized, double-blinded, placebo-controlled, Phase 1 study (abstract ID: #2464, poster ID: P0343)
Poster 2: Eblasakimab, a monoclonal antibody targeting IL-13Ra1, reduces serum biomarkers that are associated with atopy and correlated with disease severity, in patients with moderate-to-severe atopic dermatitis (abstract ID: #932, poster ID: P0243)
Poster 3: Eblasakimab improves itch and sleep loss in adult patients with moderate-to-severe atopic dermatitis in a randomized, double-blinded, placebo-controlled, Phase 1 study (abstract ID: #2459, poster ID: P0342)
¦{门¬¥©¬§J©M·s¥[©Y¡A2022¦~8¤ë11¤é¡]GLOBE NEWSWIRE¡^--ASLAN Pharmaceuticals¡]纳´µ达§JªÑ²¼¥N码¡GASLN¡^¬O¤@®a处¤_临§É阶¬q¡B¥H§K¬Ì学为«点ªº¥Íª«¨î药¤½¥q¡AP¤O¤_开发§ï变±wªÌ¥Í¬¡ªº创·s疗ªk¡C2022¦~8¤ë11¤é¡]GLOBE NEWSWIRE¡^--ASLAN Pharmaceuticals¡]纳´µ达§JªÑ²¼¥N码¡GASLN¡^¬O¤@®a处¤_临§É阶¬q¡B¥H§K¬Ì学为«点ªº¥Íª«¨î药¤½¥q¡A¥¿¦b开发§ï变±wªÌ¥Í¬¡ªº创·s疗ªk¡A¤µ¤Ñ«Å¥¬¡A¤T¥÷®i¥ÜÉO¥ì¥¬©Ô¦è单§Ü¦³关ªº·s发现ªººKn将§@为电¤l®ü报¦b²Ä31届欧¬w¥Ö肤¯f©M©Ê¯f学会¡]EADV¡^¤j会¤W®i¥Ü¡A该¤j会将¤_2022¦~9¤ë7¤é¦Ü10¤é¦b·N¤j§Q¦Ì兰¥H现场©M虚úQ¤è¦¡举¦æ¡C
²Ä31届欧¬w¥Ö肤¯f学©M©Ê¯f学学会¤j会电¤l®ü报详±¡
®ü报1¡G¦b¤@项随Éó¡B双ª¼¡B¦w¼¢剂对·Óªº1´Á¬ã¨s¤¤¡AEblasakimab§ïµ½¤F¤¤««×¯S应©Ê¥Öª¢¦¨¦~±wªÌªº¦hÏú¯e¯f«ü标 (Abstract ID: #2464, poster ID: P0343)
®ü报2¡GEblasakimab¡A¤@Ïú¹v¦VIL-13Ra1ªº单§J¶©§ÜÊ^¡A¥iú£¤Ö¤¤««×¯S应©Ê¥Öª¢±wªÌªº¦å²M¥Íª«标§Óª«¡A这¨Ç标§Óª«ÉO¯S应©Ê¦³关¡A¦}ÉO¯e¯f严«µ{«×¬Û关¡C (Abstract ID: #932, poster ID: P0243)
®ü报3¡G¦b¤@项随Éó¡B双ª¼¡B¦w¼¢剂对·Óªº1´Á¬ã¨s¤¤¡AEblasakimab§ïµ½¤F¤¤«×¦Ü««×¯S应©Ê¥Öª¢¦¨¦~±wªÌªºæ±Ö}©MºÎ¯v¤£¨¬问题 (Abstract ID: #2459, poster ID: P0342)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/8/11 ¤U¤È 04:14:57
²Ä 5439 ½g¦^À³
|
Tralokinumab ¥h¦~©³®³¨ìFDA¬ü°êÃįg¡AEASI75ªº¤T´ÁÁ{§ÉÀø®Ä¬ù25%¥u¦³Dupilumabªº¤@¥b¡C ¦ý¦h¹ï·Ó²Õ¤@¿¡]100%¡^¡C
Dupilumab ¤T´Á¦h¹ï·Ó²Õ2.73¿(273%)¡X¡X48.5% vs13%
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/8/11 ¤U¤È 04:00:38
²Ä 5438 ½g¦^À³
|
¬õ¹Ð¤j¡A
¤T´ÁÁ{§É¥²¶·°µ¡C ¥Ø«e§ä¤£¨ìÃÄÃÒ¤£¹Lªº²z¥Ñ¡I
¦pªGEASI75ªºÀø®ÄASLAN004Àu©ó¤éDupilumab40%¡]69%/48¡D5¢H¡^¨º¥[004ªºÃÄÃÒ»ùÈ´N«D±`¡B«D±`°ª¡C
¤W¥«¾P°â5¦~¤º¥i±æ¶W¶VDupilumab¡C
¥un©M |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2022/8/11 ¤U¤È 02:23:54
²Ä 5437 ½g¦^À³
|
½Ð±Ð¤Ñ©R¤j ·sªºMOA¤@¦ý½T»{¡A¥i¥H½T©wÃÄÃÒ¥²¹L¶Ü¡H ¥i¥H½T»{·|¦³¨º¨Ç§Q¦h |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2022/8/11 ¤W¤È 10:46:53
²Ä 5436 ½g¦^À³
|
CNTB¤£¥Î¤½¥¬¦Û¤vªºMOA¶Ü??? ¨Ì³W©w¬O¤£¥Î¤½¥¬ ÁÙ¬O¤£´±¤½¥¬ ©È¤@¤½¥¬MOA,µ²ªG¸òDupilumab¤@¼Ë. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/8/11 ¤W¤È 09:04:33
²Ä 5435 ½g¦^À³
|
´Á«Ý¥Î·sM0A¨Ó¸ÑÄÀ¡Bµý©ú¡AÀø®ÄÀu©óDupilumab. ¦Ü¤ÖÀu42%ªº¥i¯à¡C
69% vs 48.5%=142% |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/8/11 ¤W¤È 08:55:30
²Ä 5434 ½g¦^À³
|
³¯¤j¡Aµ¥9¤ë15¤é¡A¥Ñ¤½¥qªºÂàÄÀÂå¾Ç¹êÅçµ²ªG¨Ó§i¶D§ÚÌ¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2022/8/11 ¤W¤È 08:03:11
²Ä 5433 ½g¦^À³
|
Ãø©Ç³Ìªñ·à¤l¦³¨Ç°Ê¤F ·à¤l¥[ªo¡A¤£n¿éµ¹CNTB |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/8/11 ¤W¤È 07:30:58
²Ä 5432 ½g¦^À³
|
½Ð°Ý¤Ñ©R¤j
004 MOA ¤£¬O¤w½T»{¤F
¬°¦óÁÙ¦³·sªºMOA |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2022/8/10 ¤U¤È 01:58:20
²Ä 5431 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/8/10 ¤U¤È 12:02:25
²Ä 5430 ½g¦^À³
|
stocktwits.com/symbol/ASLN
ASLN ±N©ó9¤ë15¤é 10:00~13:00 ¦b¯Ã¬ù Á|¿ìR&D Day.
1.µoªíASLAN004 1b , PRO DATA, 2.µoªíASLAN004 ·sMOA 3.¥¼¨ÓASLAN004ªºÁ{§É |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/8/7 ¤W¤È 10:48:55
²Ä 5429 ½g¦^À³
|
sec.report/Document/0001193125-22-176648/
CNTB p¹º¤½¶}¥«³õÄw资3»õ¬ü¤¸¡C
¥Ø«e¥«È7¤d2¸U¬ü¤¸¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/8/6 ¤U¤È 05:33:39
²Ä 5428 ½g¦^À³
|
CNTB ¤W¶g±q0.81º¦¨ì1.32¬ü¤¸/ªÑ.¤wº¦50%
7¤ë12¤é«Å¥¬ ,CBP-201 ¤¤°êAD 2B,255¤HÁ{§É,¦~©³¸Ñª¼.
finance.yahoo.com/quote/CNTB?p=CNTB
CNTB ¶·±q¥«³õ¤j¶Ò¸êª÷°µAD 3´Á.
---------------------------------------
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2022/8/4 ¤W¤È 10:11:33
²Ä 5427 ½g¦^À³
|
¥Dn¬O50%¤H¼Æ¡A¦ý¤]n°t¦X¦¬®×¤¤¤ß¤@¦¸¦¬®×¤¤Hªº¦¬¶°¼Æ¾Úªº§¹¾ã©Ê¡A¬G59/2=29.5¬Û·í©ó30Ó¦¬®×¤¤¤ß¡A¬G30*5¤H=150¤H¬O¤ñ¸û¥¿±`ªºª¬ªp~ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/8/3 ¤U¤È 05:31:36
²Ä 5426 ½g¦^À³
|
½Ð°Ý¤j¤j
´Á¤¤¼Æ¾Úªº¤½§G³Ì§Cµ{«×¶È»Ýn50%¦¬®×¤H¼Æ§¹¦¨16¶gªº¸ÕÅç¡A
¬O«ü¤w§¹¦¨©Û¶Ò45³B¤§50%¦¬®×¤H¼Æ
ÁÙ¬O«üìpµe©Û¶Ò59³B¤§50%¦¬®×¤H¼Æ ¤H¼Æ»Ý¹F59*5=295¡A295*50%=148¤H§¹¦¨16¶gªº¸ÕÅç¡A
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2022/8/3 ¤W¤È 08:02:02
²Ä 5425 ½g¦^À³
|
¤w§¹¦¨©Û¶Ò¤¤¤ßªº¶}³]µ{«×~ 45/59*100%=76.2%
¦Ó´Á¤¤¼Æ¾Úªº¤½§G³Ì§Cµ{«×¶È»Ýn50%¦¬®×¤H¼Æ§¹¦¨16¶gªº¸ÕÅç¡A¥[¤W3-4¶gªº¼Æ¾Ú¾ã²z¡A«Ü¦³¾÷·|¦b¦~©³«e¤½¥¬¥¿¦V´Á¤¤¼Æ¾Ú...¥[ªoªü·à
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/8/2 ¤W¤È 06:39:25
²Ä 5424 ½g¦^À³
|
www.clinicaltrials.gov/ct2/show/NCT05158023
004 2bÁ{§É¡C©Û¶Ò¤¤¤ß¼W¥[¦Ü45³B¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G§d½n¶¯10142119 |
µoªí®É¶¡:2022/7/27 ¤U¤È 09:08:40
²Ä 5423 ½g¦^À³
|
¤U¥b¦~...003¡Bprodata¡B2b´Á¤¤... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2022/7/27 ¤U¤È 05:23:36
²Ä 5422 ½g¦^À³
|
³o¬O¤@Ó»P®É¶¡Áɶ]ªº°Ó·~Ävª§¼Ò¦¡¡G 1.110¦~3¤ë¶Ò¸êªº¿ú¥u¯à¥Î¨ì112¦~©³¡C 2.ªÑ»ùÀ³©ó112¦~3¤ë«e°ª©ó1¬ü¤¸³sÄò10¤Ñ¡C ¤Wz¨âÂI¬O½T©wªº¡C ------------------------------------------------------¨È·à±d§@ªk----------------------------------------------------- 1.112¦~2¤ë«e´¦ÅS004¤G´ÁÁ{§É´Á¤¤³ø§i©Ô°ªªÑ»ù¡C 2.112¦~¤W¥b¦~004¤G´ÁÁ{§É¸Ñª¼«á¶Ò¸ê¡C 3.¶Ò¸ê·í¤U±N¬O¥þ²y«e¤¤jÃļt¤ñ½Öªº¤f³U²`ªº®ÉÔ¤F¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2022/7/21 ¤W¤È 08:15:38
²Ä 5421 ½g¦^À³
|
¦~©³Y¨S¦³´Á¤¤³ø§i¡AªÑ»ùn¤W1¤¸¥O¤H¾á¤ß ·Pı¤½¥qÀ³¸Ó¥X¨Óµ¹Ó§ó©ú½Tªº¹wp´Áµ{ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/7/20 ¤W¤È 10:51:30
²Ä 5420 ½g¦^À³
|
2019/02 ,Dermira ¦A±Â¥X¼Ú¬wLebrikizumab °Ó·~¤ÆÅv¤Oµ¹Almirall,¤½¥q.
Out-License and Other Agreements Almirall Agreement
2019¦~6¤ë30¤é¬°1.10»õ¬ü¤¸¡A¨½µ{ª÷+¾P°â¨½µ{ª÷?+¾P°â¤À¼í? ¨ä¤¤¥]¬A¡G¡]i¡^3000¸U¬ü¤¸ªº«e´Á´ÁÅv¶O; ¡]ii¡^5,000¸U¬ü¤¸ªº´ÁÅv¦æÅv¶O¡F ¡]iii¡^3000¸U¬ü¤¸ªº¨½µ{¸O --------------------------------------------------- 3.2019/05/31 , CSL»P¨È·à2014¦~°_¦@¦P¶}µo,§Q¼í¦U¥b. 1a °µ§¹ CSL ¨È·à¦@¦P±ÂÅvASLAN004 ¥þ²yµo®i/¥Í²£/°Ó·~¤Æµ¹ ¨È·à±d, (±ÂÅvª÷=(«eª÷+¨½µ{ª÷ 1.25»õ¬üª÷ +³Ì°ª¹F 6.55 »õ¤§¾P°â¨½µ{ª÷)*2=7.8*2»õ¬üª÷)+ (¥[¾P°â¤À¼í5%~<= 10%.)*2 ¦U±o¤@¥b.
ASLAN004 ¶i¤J¤T´Á«e¶·¤ä¥ICSL 3000¸U¬ü¤¸, ¨úÃĵý¤ä¥I9250¸U¬ü¤¸.
¤½¥q¥²¶·¥Hªø¤[¸gÀç¥h¦Ò¶q¸êª÷, §¨Ó¨ÖÁÊDermira (Lebrikizumab)¤½¥qµû¦ô¦bAD¤G´Á¸Ñª¼«á¤~¶}©l.(¨ì«Å§G¨ÖÁʬù11Ó¤ë)
1B 8¶gªvÀø¥u¦¨¥\ÅçÃÒMOA 2B 16¶gªvÀø©MDupilumab ¤T´Á16¶gÀø®Ä¤ñ, ¯à¤ñ¸û¤½¥µû¦ôaslan004»ùÈ.
¨Ì·Ó§¨Ó¨ÖÁÊDermira (Lebrikizumab)¤½¥qµû¦ô, ASLN ¤½¥q2023¦~©³³Q¨ÖÁʬO¸û¦X²z¹w¦ô.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2022/7/20 ¤W¤È 10:30:26
²Ä 5419 ½g¦^À³
|
§ÚÁ`ı±o¡¨¼Ú¬w°Ï±ÂÅv¡¨¬OºØ°g«ä¡C ¥þ²y«e¤¤jÃļt³£¤w¸gª¾¹DÁÉ¿Õµá§ùÁת¢ªº¾P°âÃB¤F¡A¬°¦óÁÙn¨Ó¸ò¨ä¥LÃļtÄvª§¨È·à±d004ªº¼Ú¬w°Ï±ÂÅv¡H¡H ¤¤jÃļt¤@©w¬O¤ñ½Öªº¤f³U²`¡Aª½±µ§â¨È·à±d¨Ö¤F¡C¤T´Á¯dµ¹¨ÖÁʤ½¥q¦Û¤v§@¡C ¬yµ{¦p¤U¡G 1.´Á¤¤³ø§i¤½¥¬(ªÑ»ù«e¤@Ó¤ë¶}©l°Ê) 2.´Á¤¤³ø§i¤½¥¬«á¡A¥þ²y«e¤¤jÃļt¶}©l»P¨È·à±d±K¤Á±µÄ²½Í¨ÖÁÊ¡C 3.¦¹®É¨ÖÁÊ»ù³Ì«K©y¡A¤£nµ¥¨ì2bÁ{§É¸Ñª¼¡C 4.µ¥¨ì2bÁ{§É¸Ñª¼(¦P®É¶}©ñ¼Ú¬w°Ï±ÂÅv)¡A¦A¨Ó½Í¨ÖÁÊ¡A¨ÖÁÊ»ù´N¶Q¤F¡C (³o¬O§ÚªºÅÞ¿è¡A«e´£¬O004ÃĮĤñ§ùÁת¢¦n(ÃĮİÝÃD¤Ñ©R¤j¤j¬O±M®a))
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/7/20 ¤W¤È 09:38:58
²Ä 5418 ½g¦^À³
|
¤U¥b¦~¦ôp§¹¦¨¨½µ{ 1.2b 295 ¤HÁ{§É¡A¦¬®×§¹¦¨(9-10¤ë) 2.¤½§G1b ¥Íª««ü¼ÐªºÀø®Ä 3.¤½§G004ªºAD¿W¯SMoA
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/7/20 ¤W¤È 09:29:46
²Ä 5417 ½g¦^À³
|
004 ªº2b¸Ñª¼¤Î欧¬w°Ïªº±ÂÅv ¥²¶·¬°Äw资5-6»õ¬ü¤¸¡C
´Á¤¤³ø§i«á¡A¦p¯àªÑ»ù©Ô¤W8¬ü¤¸/ªÑ¡A
¥H6.4¬ü¤¸/ªÑ¶Ò资¡A¤~ȱo¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2022/7/20 ¤W¤È 09:22:08
²Ä 5416 ½g¦^À³
|
ÅÞ¿è«ä¦Ò¡G 3¤ë©³¦]ªÑ»ù§C©ó1¬ü¤¸¡A³Qĵ§i©µ«á6Ó¤ë§ïµ½(§Y9¤ë©³«eªÑ»ùn°ª©ó1¬ü¤¸³sÄò10¤Ñ)¡A ¦Ó9¤ë©³©¡º¡¤]¥u¯à¦A©µ6Ó¤ë¡A§Y112¦~3¤ë©³YªÑ»ù¤´§C©ó1¬ü¤¸¡A«h±N³Qn¨D¤U¥«¡C ¨È·à±dY¦Ò¼{±N¼Ú¬w±wªÌ¦C¤JªvÀø¡AµM«á¨Óµ¥©ú¦~3¤ëªº¸Ñª¼¡C³o¼Ë®É¶¡¤Ó»°¡B·ÀI¤Ó¤j(¸ê®Æ¾ã²z¤£¤Î)¡C ¤@©w·|¦³´Á¤¤³ø§i¡A®É¶¡¸¨©ó111¦~12¤ë¦Ü112¦~2¤ë¤½¥¬´Á¤¤³ø§iªº¾÷·|«Ü¤j(²Å¦XÅÞ¿è)¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/7/19 ¤U¤È 06:03:30
²Ä 5415 ½g¦^À³
|
Ó¤H¦ôp
¦~©³¯à§¹¦¨16¶gªvÀøªº43*5=215¤H(+215/295=73%)¦³¾÷·|. (Y¦³»Ýn¦~©³¥i´Á¤¤³ø§i)
¨ä¥L¼Ú¬w±wªÌ¥i¯à9¤ë¤¤¤U¦¯¶}©lªvÀø,©ú¦~¤¸¤ë~2¤ë©³¦³¾÷·|§¹¦¨295¤H 16¶gªvÀø. ©ú¦~3¤ë¸Ñª¼«Ü¤j¥i¯à. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2022/7/19 ¤W¤È 11:14:56
²Ä 5414 ½g¦^À³
|
¥J²Ó¹LÂo¦¬®×ªº«~½è(¿z¿ï¶Ç²ÎAD±wªÌ),ÁÙ¬O«Ü¦³¾÷·|¦b¦~©³«e¤½¥¬¥¿¦Vªº´Á¤¤¼Æ¾Ú~~~~ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/7/15 ¤U¤È 10:49:36
²Ä 5413 ½g¦^À³
|
clinicaltrials.gov/ct2/show/NCT05158023?term=Aslan004&draw=2&rank=3 ASLAN004 AD 2b Á{§É ¼W¥[¦L«×¤@Ó¦¬®×¤¤¤ß¡A²Öp¥þ²y43Ó¦¬®×¤¤¤ß¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/7/14 ¤U¤È 04:05:24
²Ä 5412 ½g¦^À³
|
Lebrikizumab ý³Ý¤ÎCOPD ¤T´Á¥¢±Ñ,ªvÀø AD¨Öµo¯gªº¥\¯à¤£¤ÎDupilumab ¦b¤@½uÃÄÄvª§¤O®t,¬G¸Õ§ä¤G½uÃÄ¥«³õ.
¦ý¦]MOA ©MDupilumab ¦P¬°«¬¤Gª¢¯g¸ô®|¤§¤@. ¥»¦¸·sAD¤G½u¤T´Á¯à§_¦¨¥\???¥¼ª¾
À³¥u¦³¦b¥Îdupilumab ¦³AE/µ²½¤ª¢°Æ§@¥ÎªÌ¨¤W¤~¦³¤ñ¸û¨ÎªºÀø®Ä§a!(Öt¹ê¬ã¨s¬ùdupilumap 25%~35%µ²½¤ª¢) |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/7/14 ¤U¤È 03:01:42
²Ä 5411 ½g¦^À³
|
¥Íª«¦Û§ä¥Í¸ô
¥ÎDupilumabµL¤ÏÀ³ªÌ¦b¤T´ÁÁ{§É¬ù35%,¹FEASI75ªÌ¬ù48.5%.
§¨Ó¶}Lebrikizumab (LY3650150) ¶}-««×AD ¤G½u¥ÎÃÄ(¥ÎDupilumab µL¤ÏÀ³©ÎAE¦ÓµLªk¨Ï¥ÎªÌ) ¤T´ÁÁ{§É 120¤H.
Study Design Go to sections Study Type : Interventional (Clinical Trial) Estimated Enrollment : 120 participants Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: An Open-Label, Study to Evaluate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab Estimated Study Start Date : August 18, 2022 Estimated Primary Completion Date : August 2, 2023 Estimated Study Completion Date : December 6, 2023
clinicaltrials.gov/ct2/show/NCT05369403?term=Lebrikizumab&draw=2&rank=3
A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab
纳¤J标ã¡C
©Ò¦³参ÉOªÌ¤§«e¥²须±µ¨ü过²Å¦X¥H¤U条¥ó¤§¤@ªº§ù¤Ç鲁(dupilumab)单§Üªv疗¡C
¦]ÆÓ¤Ï应¡B³¡¤À¤Ï应¡B¥¢¥h疗®Ä¦Ó°±¤î§ù¤Ç鲁单(dupilumab)§Üªv疗ªº参ÉOªÌ¥²须¤§«e±µ¨ü过§ù¤Ç鲁单§Ü¡]标ª`剂¶q¤ô¥¡^ªv疗¦Ü¤Ö4个¤ë¡C ¦]对药ª«¤£@¨ü©Î发¥Í¤£¨}¨Æ¥ó¡]AEs¡^¦Ó°±¤î§ù¤Ç鲁单§Üªv疗ªº参ÉOªÌ¥i¥H进¤J¬ã¨s¡A¦Ó¤£n¨D¤§«e§ù¤Ç鲁单§Üªv疗ªº时间¡C ¦]费¥Î问题©ÎÆÓªk获±o§ù¤ñ卢单§Ü¡]¦p«O险¡^¦Ó°±¤î§ù¤ñ卢单§Üªv疗ªº参ÉOªÌ¡A¥i¥H¦b没¦³n¨D¤§«e§ù¤ñ卢单§Üªv疗时间ªº±¡úG¤U进¤J¬ã¨s¡C
Inclusion Criteria:
All participants must have prior treatment with dupilumab meeting one of the following conditions:
Participants who stopped dupilumab treatment due to non-response, partial response, loss of efficacy must have been previously treated with dupilumab (at labeled dose level) for at least 4 months.
Participants who stopped dupilumab treatment due to intolerance or adverse events (AEs) to the drug may enter the study with no required prior length of dupilumab treatment.
Participants who stopped dupilumab treatment due to cost or loss of access to dupilumab (for example, insurance coverage) may enter the study with no required prior length of dupilumab treatment. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2022/7/13 ¤U¤È 08:03:41
²Ä 5410 ½g¦^À³
|
±bºÞ¶OÀ³¸Ó¨C¶¡°Æ©e°U¦¬ªº®É¶¡³£¤£¤@¼Ë À³¸Ó¥i¥H½ÐÀç·~ûÀ°§Aª`·Nn¦¬¶O®É³qª¾ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2022/7/13 ¤U¤È 07:52:15
²Ä 5409 ½g¦^À³
|
Adr«OºÞ¶O ¤£¬O¤¤ë¤U¦¯¤w¸g¦¬¤F ?
La Jolla Pharmaceutical «Ü·|½æ¤½¥q
Innoviva ¥H¨CªÑ 6.23 ¬ü¤¸ªº²{ª÷©ÎÁô§tªº¥ø·~»ùȦ¬ÁÊ La Jolla ªº©Ò¦³¬y³qªÑ¬ù 1.49 »õ¬ü¤¸¦¬ÁÊ La Jolla »sÃĤ½¥q
La Jolla ªº¥D¾É²£«~ GIAPREZA ®¡]¦åºÞºò±i¯À II¡^©ó 2017 ¦~ 12 ¤ëÀò±o¬ü°ê¹«~ÃÄ«~ºÊ·þºÞ²z§½ (FDA) ªº§åã¡A¥Î©ó¼W¥[·P¬V©Ê©Î¨ä¥L¤À§G©Ê¥ð§J¦¨¤Hªº¦åÀ£ ¤À§G©Ê¥ð§J ±Ñ¦å©Ê¥ð§J¡]Septic Shock¡^ ¹L±Ó©Ê¥ð§J(©ÎºÙµL¨¾¿m©Ê¥ð§J¡Aanaphylactic Shock) ¯«¸g©Ê¥ð§J¡]Neurogenic Shock¡^
La Jolla ²Ä¤G¶µ²£«~ XERAVA ®¡]®J©Ô¥ËÀô¯À¡^©ó 2018 ¦~ 8 ¤ëÀò±o FDA §åã¡A¥Î©óªvÀø 18 ·³¤Î¥H¤W±wªÌªº½ÆÂø¸¡µÄ¤º·P¬V¡] cIAI ¡^
GIAPREZA :ºI¦Ü2021 ¦~ 9 ¤ë 30 ¤éªº¤EÓ¤ë¡AGIAPREZA ¬ü°ê²£«~²b¾P°âÃB¬° 2430 ¸U¬ü¤¸¡A¸û 2020 ¦~¦P´Á¼Wªø 18%¡C
XERAVA ºI¦Ü 2021 ¦~ 9 ¤ë 30 ¤é¤î¤TÓ¤ë¡AXERAVA ¬ü°ê²b²£«~¾P°âÃB¬° 290 ¸U¬ü¤¸
GIAPREZA+XERAVA ¨â¶µ²£«~¤@¦~¾P°âÃB¤£¨ì5000¸U¬ü¤¸ Innoviva ¥H¨CªÑ 6.23 ¬ü¤¸ªº²{ª÷©ÎÁô§tªº¥ø·~»ùȦ¬ÁÊ
La Jolla , La Jolla Pharmaceutical Company «Ü·|½æ¤½¥q
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/7/13 ¤U¤È 07:39:32
²Ä 5408 ½g¦^À³
|
clinicaltrials.gov/ct2/history/NCT05158023?A=6&B=7&C=Side-by-Side#StudyPageTop
ASLAN004 2bÁ{§É¦¬®×¤¤¤ß¡A¦A¼W3Ó¡]¿D¬w¡A¦L«×¡A·s¥[©Y¦U1¡^¡A²Öp42Ó¡C⋯⋯⋯³Ì·s¸ê®Æ¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2022/7/13 ¤W¤È 08:27:06
²Ä 5407 ½g¦^À³
|
Tang Capital Management, LLC ¬O¥Ø«e«ù¦³¨È·à±dªÑÅv³Ì°ªªº°òª÷¤½¥q
Tang Capital Management, LLC (Tang Capital) is a life sciences-focused investment firm with a strong track record of creating and building successful biopharmaceutical companies. The principal of Tang Capital founded Ardea Biosciences, Inc. in 2006 and served as its director until its acquisition by AstraZeneca PLC in June 2012. The principal of Tang Capital currently serves as Chairman of Heron Therapeutics, Inc. (NASDAQ: HRTX), La Jolla Pharmaceutical Company (NASDAQ: LJPC), and as the Chairman and Chief Executive Officer of Odonate Therapeutics, Inc. (NASDAQ: ODT). Tang Capital manages an investment fund that is the largest shareholder of all three of these companies. Tang Capital currently has offices in San Diego and New York.
Tang Capital Management, LLC ºX¤ULa Jolla Pharmaceutical Company (NASDAQ: LJPC) «e¤Ñ«Å¥¬(7¤ë11¤é)³Q¦¬ÁÊ
Innoviva to Acquire La Jolla Pharmaceutical Company
BURLINGAME, Calif. & WALTHAM, Mass., July 11, 2022--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, and La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that they have entered into a definitive merger agreement whereby Innoviva will acquire La Jolla. Innoviva has agreed to pay $5.95 per share for La Jolla, representing a premium of approximately 70% to the 30-day volume-weighted average price (VWAP), and an incremental $0.28 per share for additional cash proceeds received in connection with the divestiture of a non-core asset. Under the terms of the merger agreement, Innoviva, through a wholly owned subsidiary, will commence a tender offer on or before July 25, 2022 to acquire all of the outstanding shares of La Jolla for $6.23 per share in cash, or an implied enterprise value of approximately $149 million.
²{¦b Tang Capital Management, LLC ¤â¤W²{ª÷º¡º¡ ·|«ùÄò¤j¤O¥[½X¨È·à±d¶Ü?
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2022/7/12 ¤U¤È 08:38:12
²Ä 5406 ½g¦^À³
|
¦³¤Hª¾¹Dú«OºÞ¶O°ò·Ç¤é¬Oþ¤@¤Ñ¶Ü? ªÑ»ù¤U¶^ÁÙ¦¬¡A¯u¬O¤Ó¥W¤F |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/7/9 ¤W¤È 09:59:08
²Ä 5405 ½g¦^À³
|
¤S¨ì¤Fnúadr«OºÞ¶O®É¶¡ ½Ð°Ý«OºÞ¶O¬O¨CªÑ0.03¤¸Áâ¶Ü
¬Ý¨ì²{ªÑ¤~0.52¤¸¡A¹ê¦b¦³ÂIµS¿Ý
¤£ª¾¥¼¨Ó¦³¾÷·|¶Ü |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/7/8 ¤W¤È 08:37:03
²Ä 5404 ½g¦^À³
|
ADC °ê»Ú±ÂÅv
2016¦~ 2¤ë,Immunomedics¤½¥q IMU-132 (Sacituzumab Govitecan-hziy)ADC ÀòBTD(¬ð¯}©ÊÀøªk),2016¦~12¤ëªÑ»ù3¬ü¤¸/ªÑ¥ª¥k.¥¦ªº¤W¥«¦b¬°¤T³±¨ÅÀùªºªvÀø3½u«ámTNBC.
2017¦~ 2¤ë, Immunomedics¤½¥q ´¿±NIMU-132 ADC ¥þ²y¾P°âÅv¥H20»õ¬ü¤¸±ÂÅvµ¹Seagen¤½¥q, «á¨ÓImmunomedics¤½¥q¤jªÑªF§_¨M¦¹±ÂÅv¨Ã¶}°£CEO.
2019¦~4¤ë¡A ¤é¥»²Ä¤@¤T¦@±ÂÅvADC µ¹AZªü´µ§Q±d»P²Ä¤@¤T¦@´NEnhertu ñ¸pªº°ª¹F69»õ¬üª÷ªº¦X§@¨óij ¡BEnhertu¬OÄ~ù¤óKadcyla¤§«á²Ä¤GÓÀòã¥Î©óHer2¶§©Ê¨ÅÀùªºADC¡A¤£¶È¦b±ß´ÁHer2¶§©Ê¨ÅÀù¤Wªí²{üL«l¡A¤]¬O³Ì¦³¼ç¤O¦bGÀù¡BNSCLCµ¥¹êÅé½F¤W¦³©Ò¬ð¯}ªºADC¡C
2020¦~¡A ¤é¥»²Ä¤@¤T¦@±ÂÅv²Ä¤GÓADC µ¹AZªü´µ§Q±d»P²Ä¤@¤T¦@´NEnhertu ñ¸pªº°ª¹F¬ù60»õ¬üª÷ªº¦X§@¨óij
2020¦~¦N§Q¼w¥H 210 »õ¬ü¤¸(¬ù90¬ü¤¸/ªÑ)ªº°ª»ù¦¬ÁʤFADC¤½¥q Immunomedics¡A ³Ð¤U·í¦~³Ì°ª¥æ©ö¬ö¿ý¡C ·s¹vÂITROP-2 -----------------------------------------------------------------------------------------
2021¦~ºa©÷¥Íª«±ÂÅvADCÃĪ«µ¹¦è¶®¹Ï°ò¦]2»õ¬ü¤¸º¥I©M24»õ¬ü¤¸¨½µ{¸O³Ð¤U¤j³°26»õ¬ü¤¸±ÂÅv¬ö¿ý¡C
2022.6.21Àq¨FªF±ý400»õ¬ü¤¸¦¬ÁÊADC¡]§ÜÅé°¸ÁpÃĪ«¡^ª¾¦W¥ø·~Seagenªº®ø®§¶Ç¥X¡A¤]ÅýADCÃĪ«¦A¦¸¨ü¨ìÃöª`¡C ---------------------------------------------------------------------------------------------- 2022 ¥xÆW¯E¹©¤µ¦~¥H2»õ¬ü¤¸±ÂÂg OBI-999 ADC,¤j³°°Ï¾P°âÅv(¬ù¦û¥þ²y¾P°â11%) µ¹»´äÃö«Y¥ø·~ ¦P®É¨ú±o¤j³°¤½¥q¹vÂITROP-2 ADC ±ÂÅv |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/7/8 ¤W¤È 07:38:40
²Ä 5403 ½g¦^À³
|
Àq§J¶Ç¯{¹O¥ü¤¸°ùSeagen ¥i±æ¦¨¬°¤µ¦~³Ì¤j¥Í§Þ¨ÖÁÊ®× 2022/07/07 18:24
°]°T·s»D¤¤¤ß
Àq§JY¦¨¥\¨ÖÁÊSeagen¡A±N¦¨¬°¤µ¦~³Ì¤j¥Í§Þ¨ÖÁÊ®× Àq§J¤½¥q¡]Merck & Co. Inc., MRK¡^¥¿¦b´N¦¬ÁÊSeagen Inc. ¡]SGEN¡^¨Æ©y¶i¦æ²`¤J½Í§P¡A¥´ºâ¦b¥¼¨Ó´X©P¤ººV©w¹ï³o®aÀù¯g¥Íª«§Þ³N¤½¥qªº¦¬ÁÊ¥æ©ö¡A³oµ§¥æ©öªº»ùÈ¥i¯à¦b¤j¬ù400»õ¬ü¤¸¡]1.2¥ü¤¸¥x¹ô¡^©Î§ó°ª¡A¦¨¬°¤µ¦~³Ì¤j¤@µ§¥Í§Þ¨ÖÁʮסC
µØº¸µó¤é³ø¤Þ¥Î¾Úª¾±¡¤H¤h³zÅS¡AÀq§J»PSeagen¨â®a¤½¥q¥¿¦b°Q½×¥H¤£§C©ó¨CªÑ200¬ü¤¸ªº»ù®æ¦¬ÁÊSeagenªº¥i¯à©Ê¡A¨Ã´M¨D¦bÀq§J¤½¥q¤½¥¬²Ä2°]©u·~ÁZ®É©Î¤½¥¬°]³ø«eºV©w¦¬ÁÊ¥æ©ö¡C
¥Ñ©óÀq§J¤½¥q©w©ó7¤ë28¤é¤½¥¬²Ä2°]©u·~ÁZ³ø§i¡A¥«³õ¹w´Á¥æ©ö®×³Ì§Ö¤ë©³«e¤½§i¡CSeagenªÑ»ù©P¤T¦¬©ó175.13¬ü¤¸¡C¤£¹L¥Ø«e¤´¤£¯à«OÃÒÀq§J¤½¥q©MSeagen¤@©w·|´N¨ÖÁÊ¥æ©ö¹F¦¨¤@P¡C
¤µ¦~¥H¨Ó¥Í§Þ·~¨ÖÁÊÀW¶Ç¡APGIM«O¼w«H¥þ²yÂåÀø¥Í¤Æ°òª÷²Îp¡A6¤ëªì¥²ªv§´Ãļt«Å¥¬¥HÁ`ª÷ÃB¬ù41»õ¬ü¤¸¡A¨ÖÁʥͪ«¬ì§Þ¤½¥qTurning Point¡A
5¤ë©³¸¯Äõ¯ÀÃļt¥H21»õ¬ü¤¸¦¬Áʬü°ê¥Í§Þ¤½¥qAffinivax¡B
½÷·ç¥H116»õ¬ü¤¸¨ÖÁÊBiohaven Pharmaceutical¡AÅã¥Ü2022¦~¥Í§Þ¨ÖÁʬ۷í¼öµ¸¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2022/6/30 ¤U¤È 04:16:35
²Ä 5402 ½g¦^À³
|
¤Ñ©R¤j ¤½¥q¤£¬O»¡ ASLAN 003¤W¥b¦~n¶i¤J¤G´ÁÁ{§É¡H §¨Óªº´³¨r²æ¾vÃÄOlumiant ¨S¦³³æ¿W°µ¤G´ÁÁ{§É¡A¬Oª½±µ¶i¦æ¤G/¤T´ÁÁ{§É¹êÅç³]p¡AÃø¤£¦¨¤½¥q¤]n¨«¦P¼ËÁ{§É¸ÕÅç³]p¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/6/29 ¤W¤È 07:04:36
²Ä 5401 ½g¦^À³
|
³¯¤j¡A
¦Ü¤Ö¶}59Ó¦¬®×¤¤¤ß¡C¨C¤¤¤ß¦¬5±wªÌ¡A¦Xp295¤H¡C
7¤ë¡A8¤ë¡A2Ó¤ë¡A¼Ú¬w¤½¥q¤j¦h©ñ´»°²¡C
¨Ì¾Ú¤½¥qÁ{§Ép¹º¡A 12¤ë15¤é¡A§¹¦¨ªì¨B资®Æ¦¬¶°¡A¦©°£16¶gªvÀø¡A 8¤ë¤¤¦¯¡A³Ì«á¤@¦ì±wªÌn¶}¦pªvÀø¡C
¦³ÂI¬D¾Ô©Ê¡C
Y¨Ì¤½¥q¹ï¥~«ÅºÙ2b©ú¦~¤W¥b¦~¸Ñª¼¡A则¤ñ¸û宽ÃP¡C
Lebrikizumab ¥Î13Ó¤ë¡A¤½§G2b¸Ñª¼µ²ªG¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/6/29 ¤W¤È 06:45:44
²Ä 5400 ½g¦^À³
|
½Ð°Ý¤Ñ©R¤j 004 2b¹wp¶}´XÓ¦¬®×¤¤¤ß ¦L¶H¤¤°_ªì60Ó«á¨ÓÅÜ48¡A ¥i¬O¨ì²{¦b39Ó¡A ¥Î¤F§Ö2Ó¤ë®É¶¡¤~¼W¥[3Ó ¶i«×¬O§_¦³¸¨«á ¦¬®×«á¤Sn°µ8¦Ü16¶g¸ÕÅç ·Pı³t«×ºC¤U¨Ó¤F |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/6/29 ¤W¤È 04:11:06
²Ä 5399 ½g¦^À³
|
ASLAN004 2b Á{§É¡A·s¼W3Ó¦L«×ªº¦¬®×¤¤¤ß¡A²Öp39Ó¦¬®×¡C
clinicaltrials.gov/ct2/show/NCT05158023?term=aslan004&draw=2&rank=3 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2022/6/26 ¤U¤È 05:30:22
²Ä 5398 ½g¦^À³
|
www.facebook.com/105521258684593/posts/pfbid0b42uwUZZQM4AK2JxAmUGH2nKZdeRozLz2tmmt2LVSobQLic8eH7TYBr5gvR7yBfXl/?sfnsn=mo&mibextid=POHCiDwYoCtz6yrh |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/6/24 ¤W¤È 07:23:09
²Ä 5397 ½g¦^À³
|
6/23 ¨é°Ó HC Wainwright 维«ù¥Ø¼Ð»ù8¬ü¤¸/ªÑ¡A¥¼¨Ó¤@¦~¡C
¥Ø«e¦³¤T®a¨é°Ó¥X³ø§iªº¥Ø¼Ð»ù¡A¤À§O¬°8/8/3 ¡A¬ü¤¸/ªÑ¡C
¸Ô¦p¤U¡G
www.marketbeat.com/stocks/NASDAQ/ASLN/price-target/?RegistrationCode=SocialMedia-direct&utm_source=GeneralSocialMedia&utm_medium=Social&utm_campaign=SocialMedia |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/6/23 ¤U¤È 08:09:45
²Ä 5396 ½g¦^À³
|
www.deepl.com/translator
¦]¬°¥Î¦¹Â½Ä¶App¤ñGoogle ¦n¡A¦ýdeepl ¥u¦³Â²Åé¦r¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/6/23 ¤U¤È 07:36:49
²Ä 5395 ½g¦^À³
|
¨S¦³¶S§íªº·N«ä ¥u¬O¦n©_ ·Q½Ð°Ý¤Ñ©R¤j §A¬O¥xÆW¤H¶Ü ©Î¬O¤j³°¤H ¬°¦ó³£¬O¥Î²Åé¦r |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/6/23 ¤W¤È 08:19:07
²Ä 5394 ½g¦^À³
|
JAK ¤¤-«¯g AD¤fªAÃÄ¡A¥Ñ©ó°Æ§@¥Î¹L¤j¡AFDA¦C为¥Íª«»s¾¯µLªk±±¨îªº«á½u¥ÎÃÄ¡C
¤]´N¬O¨Ï¥ÎDupilumab...µ¥¥Íª«»s¾¯µL¤ÏÀ³«á¤~¯à¨Ï¥ÎJAK§í¨î¾¯¡C
www.accessdata.fda.gov/drugsatfda_docs/label/2022/213871s000lbl.pdf
FDA ¼ÐÅÒÀÉ INDICATIONS AND USAGE ----------------------------- CIBI¾AÀ³¯g¤Î¥Î³~ CIBINQO¬O¤@ÏúJanus¿E酶¡]JAK¡^§í¨î剂¡AÓì¥Î¤_ªv疗±w¦³难ªv©Ê¤¤«×¦Ü««×¯S应©Ê¥Öª¢ªº¦¨¦~¤H¡C ¥Î¤_ªv疗难ªv©Ê¡B¤¤«×¦Ü««×¯S应©Ê¥Öª¢ªº¦¨¤H±wªÌ¡A这¨Ç±wªÌªº¯e¯f¦b¨Ï¥Î¨ä¥L¨t统©Ê药ª«¦Z¤£¯à±o¨ì¥R¤À±±¨î¡C ±w¦³难ªv©Ê¤¤««×¯S应©Ê¥Öª¢ªº¦¨¤H¡A¨ä¯e¯f¥Î¨ä¥L¨t统©Ê药ª«产«~¡]¥]¬A¥Íª«¨î剂¡^¤£¯à¥R¤À±±¨î¡C 疗¡A©Î当¨Ï¥Î这¨Ç疗ªk¤£¥i¨ú时¡C(1)
¨Ï¥Î¨î¡C¤£«Ø议将CIBINQOÉO¨ä¥LJAK§í¨î剂¡B¥Íª«¨î剂©M¨ä¥L药ª«¤@°_¨Ï¥Î¡C ¨ä¥LJAK§í¨î剂¡B¥Íª«§K¬Ì调节剂¡A©ÎÉO¨ä¥L §K¬Ì§í¨î剂¡C --------------------------DO
CIBINQO is a Janus kinase (JAK) inhibitor indicated for the treatment of adults with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable. (1)
Limitation of Use: CIBINQO is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants. --------------------------DO |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/6/22 ¤U¤È 11:12:16
²Ä 5393 ½g¦^À³
|
Event Details
A4 KOL Series: Episode 3, Dr Peter Lio Jun 22, 2022
Add to Outlook Add to Google Calendar Webcast link
ir.aslanpharma.com/events/event-details/a4-kol-series-episode-3-dr-peter-lio |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2022/6/17 ¤U¤È 10:40:03
²Ä 5392 ½g¦^À³
|
FDA §åãOlumiant¥Î©óÄY«´³¨r²æ¾vªº·sªvÀøÃĪ« «ÂIºKn (¤@)6 ¤ë 13 ¤é¡A¬ü°ê¹«~©MÃĪ«ºÞ²z§½ (FDA) §åã¤F¥Î©óªvÀøÄY«´³¨r (AA) ªºÃĪ« baricitinib (Olumiant)¡A³o¬O¤@ºØ¾ÉP²æ¾vªº¦ÛÅé§K¬Ì©Ê¯e¯f¡C (¤G) ´³¨r¨C¦~¦b¬ü°ê¼vÅT¶W¹L 300,000 ¤H¡A¸g±`¾ÉPÀY¥Ö¤W¥X²{¨r´³¡C±w¦³ÄY «´³¨rªº¤H¤]¥i¯à·|¥¢¥h¬Ü¤ò©M·û¤ò¡C (¤T) ¯Ã¬ù¥«¯Ã¬ù¤j¾Ç®Ô®æ¥§Âå¾Ç¤¤¤ß¥Ö½§¯f¾Ç°Æ±Ð±ÂÝ¥Ö½§»PÀù¯g¬ì¥D¥ô Kristen Lo Sicco Âå¾Ç³Õ¤h»¡¡A¦b baricitinib (Olumiant) Àò§å¤§«e¡AFDA §å㪺ªvÀø´³¨rªºÀøªk¬°¹s¡C (¥|) Olumiant¨â¶µ 3 ´Á¸ÕÅçµ²ªG©ó 2022 ¦~ 5 ¤ë 5 ¤éµoªí¦b¡m·s^®æÄõÂå¾ÇÂø»x¡n¤W¡C¨â¶µ¸ÕÅç¦@¯Ç¤J 1,200 ¤H¡G51.7% ªº¨ü¸ÕªÌ¬°¥Õ¤H¡A36.3% ¬°¨È¸Ç¡A8.2%¬O¶Â¤H¡C¨C¤Ñ¤@¦¸±µ¨ü 2 ²@§J (mg) »P4 ²@§Jªº¤Ú·ç§J´À¥§©Î¦w¼¢¾¯¡Cn³Q¯Ç¤J¸ÕÅç¡A¤HÌ¥²¶·±w¦³ÄY«ªº²æ¾v¡A©w¸q¬°¦Ü¤Ö 50% ªºÀY¥Ö²æ¾v¶W¹L¤»Ó¤ë¡C¦b¹ï³o¨â¶µ¸ÕÅ窺¶×Á`¤ÀªR¤¤¡A¬ã¨s¶}©l®É±wªÌªºÀY¥Ö¤ò¾vÂл\²v¶È¬° 14.5%¡CªA¥Î 4 mg baricitinib ªº¤H¤¤¦³ 39% ªº¤H¹ê²{¤FÅãµÛªºÀY¥Ö¤ò¾v¦A¥Í¡A©w¸q¬° 80% ©Î§ó¦hªºÀY¥Ö¤ò¾vÂл\¡C ¤@¦~«á¡Aªñ¥|¤À¤§¤Tªº¤HªºÀY¥Ö¤ò¾vÂл\²v¹F¨ì 90%¡C (¤) ªA¥ÎOlumiantªº¤Hªº±`¨£°Æ§@¥Î©Mĵ§i ¦b¡m·s^®æÄõÂå¾ÇÂø»x¡nªº¨â¶µ¬ã¨s¤¤¡AªvÀø´³¨rªº¦w¥þ©Ê»PªA¥Î¸ÓÃĪvÀøÃþ·Àã©ÊÃö¸`ª¢ªº±wªÌ¬Û·í¡C ³Ì±`¨£°Æ§@¥Î¬O¤W©I§l¹D·P¬V¡BÀYµh¡BÚµ½H¡B°ªÁx©T¾J¡B¦Ù¦×¬ÛÃö¦å²G¼Ð»xª«¼W¥[¡]¥i¯àªí©ú¦Ù¦×·l¶Ë¡^¡B§¿¸ô·P¬V¡B¨x酶¤É°ª¡B¤òÅnª¢¯g¡]¤òÅnª¢¡^ )¡B¯h³Ò¡B¤U©I§l¹D·P¬V¡Bäú¤ß¡B¥Í´Þ¾¹»Ã¥Àµß·P¬V¡]©À¯]µß·P¬V¡^¡B³h¦å¡B¬Y¨ÇÃþ«¬ªº¥Õ²ÓM¼Æ¶q´î¤Ö¡]¤¤©Ê²É²ÓM´î¤Ö¯g¡^¡B¸¡µh¡B±aª¬¯p¯l¡]±aª¬¯p¯l¡^©MÅ髼W¥[¡C ÁöµM FDA ¤w¸g§PÂ_ Olumiant ¬O¦w¥þ¦³®Äªº¡A¦ý¸Ó¾÷ºcn¨D¸ÓÃĪ«¹ï¨u¨£¦ý¥i¯àÄY«ªº¨Ãµo¯g¡]¦p·P¬V¡B¦º¤`²v¡B´c©Ê¸~½F¡B¥Dn¤£¨}¤ß¦åºÞ¨Æ¥ó©M¦å®ê§Î¦¨¡^µo¥X¶Â®Øĵ§i¡C ¶Â®Øĵ§i¬O FDA ¹ï¥«³õ¤WªºÃÄ«~©MÂåÀø¾¹±ñ³ÌÄY®æªºÄµ§i¡C
(¤») Olumiant ªº¼Ð»ù¬° 30 ¤Ñ 2 ²@§J¤ù¾¯ 2,497.20 ¬ü¤¸¡A¦ýªvÀø´³¨rªºÃĪ«ªº¹ê»Ú¦¨¥»±N®Ú¾Ú¾¯¶q¡]2 ²@§J©Î 4 ²@§J¡^©M«OÀI½d³ò¦Ó¦³©Ò¤£¦P¡C ¦ýªvÀø´³¨rªº¾¯¶q¦p´£°ª¦Ü4mg¡A15¤Ñªá¶O¬ù2500¬ü¤¸¡C 4²@§J ¶O¥Î¸û2²@§J¶Q , ¦³ 39% ªº¤H¹ê²{¤FÅãµÛªºÀY¥Ö¤ò¾v¦A¥Í¡A (©w¸q¬° 80% ©Î§ó¦hªºÀY¥Ö¤ò¾vÂл\) ¦p¸g¹L¤@¦~ªvÀø¡A¦³ªñ¥|¤À¤§¤Tªº¤HªºÀY¥Ö¤ò¾vÂл\²v¹F¨ì 90%¡C
¥H¤W¬O¦³ÃöOlumiant¬d¸ß¨ìªº¸ê°T , ¶È¨Ñ°Ñ¦Ò ¦p¦³¿ù½Ð§ó¥¿
¸É¥R:Aslan 003 ¦b¥H¤U¯e¯f¨ãµo®i¼ç¤O Alopecia ´³¨r²æ¾v Inflammatory bowel disease¡AIBD¡A¼ìºÅ©Êµ²¸zª¢Ulcerative colitis¡A©M§J¶©¤ó¯gCrohn¡¦s disease RA Ãþ·Àã©ÊÃö¸`ª¢
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/6/16 ¤U¤È 06:31:34
²Ä 5391 ½g¦^À³
|
ASLAN004 2b Á{§É¤ñ1bÁ{§É ¼W¥[¤U¦C¨â¶µµ{§Ç¥H¿z¿ï¶Ç²ÎAD±wªÌ
1.ASLN ¤½¥q¨Ì±wªÌ°ò½uªº°ò¥»¸ê®Æ(IgE/TRAC/¶Ý»Ä²ÓM/¨Öµo¯g...)¼f¬dÄݶDzÎAD±wªÌ«á¦X®æ,¤~·|¶i¤J¤¹ã¶i¤JÁ{§ÉÀH¾÷¤À°t.
2.±wªÌ¥[¤J«e,¤½¥q³]p´XÓ°ÝÃD,¦p¤U : ¥H¶i¤@¨B¿z¿ï¶Ç²ÎAD±wªÌ www.withpower.com/trial/phase-2-eczema-11-2021-74a37
¥H¤WCEO 6/8 °Ñ¥[Jefferies ú³°Ó²{³õ°Ýµª¬ù¦b18~21¤ÀÄÁ.
wsw.com/webcast/jeff240/register.aspx?conf=jeff240&page=asln&url=wsw.com/webcast/jeff240/asln/1843950
ir.aslanpharma.com/events/event-details/jefferies-healthcare-conference
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2022/6/15 ¤U¤È 09:47:22
²Ä 5390 ½g¦^À³
|
²æ¾vªvÀø¥«³õ¤ÀªR
www.coherentmarketinsights.com/market-insight/alopecia-treatment-market-1847
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/6/15 ¤W¤È 05:54:26
²Ä 5389 ½g¦^À³
|
º¤ä¤fªA¨rÀYÃÄ ¢Ô¢Ò¢Ï§åã 2022/06/15 05:30 ¡e½sĶ©Pi¨Z¡þºî¦X³ø¾É¡f¬ü°ê¹«~ÃĪ«ºÞ²z§½¡]FDA¡^¤Q¤T¤é§åã¬ü°ê»sÃĤ½¥q¡u§¨Ó¡v¬ãµoªº¡u·R·Àª¢¡v¡]Olumiant¡^¥Î¨ÓªvÀøÄY«¶ê¨r±wªÌ¡A¦¨¬°¬ü°ê¨C¦~¹O¤Ê¸U¦W¨ü¡u°«cÀY¡v§xÂZªº¥Ö½§¯f¤Hªº²Ä¤@¤ä¤fªAÃÄ¡C
¶ê¨r¬O¦ÛÅé§K¬Ì¯e¯f¡A¥ô¦ó¦³Åé¤òªº³¡¦ì¬Ò¥i¯à¦¨¬°±w³¡¡A¶Ç²ÎªvÀø¥H§½³¡Ãþ©T¾Jª`®g¬°¥D¡A¥i¨ë¿E¤ò¾v¥Íªø¦ý©ö´_µo¡A¤µ¦~¦b¶ø´µ¥d¹{¼ú¨å§¾x¥X¥Ï¤Ú´x·ªiªº¼v¬P«Âº¸¥v±K´µ¤§©d§Y¬°±wªÌ¡C
½ÐÄ~Äò©¹¤U¾\Ū...
¡u·R·Àª¢¡v¥H¡u¤Ú·ç´À¥§¡v¡]Baricitinib¡^¬°¾Ç¦W¤ÎÃĪ«¦¨¤À¡A¥ý¦b¤G¡³¤@¤»¦~ÀòãªvÀøÃþ·Àã©ÊÃö¸`ª¢¡A¤W¤ë¤SÀòãªvÀøªZº~ªÍª¢¦¨¦~««×±wªÌ¡C
¾Ú¹êÅçµ²ªG¡AÄY«¶ê¨r±wªÌ¦@¤@¤G¡³¡³¤H¨ü¸Õ¡A¤À¨C¤éªA¥Î¤G¡B¥|²@§J¤Î¦w¼¢¾¯²Õ¡A¤Ê¤»¶g«á¡A°ª¾¯¶q²Õªñ¥|¦¨ªø¦^¤K¦¨¤ò¾v¡B§C¾¯¶q²Õ¤Ü¤T¢Hªø¦^¤K¦¨¾v¶q |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/6/13 ¤W¤È 08:18:20
²Ä 5388 ½g¦^À³
|
§Ú¦L¶H¤¤004 2bÁ{§É¸ÕÅç¬O©e°U ±M·~¾÷ºc¿ì²z©Û¶Ò ¦³Ãö¥l¶Ò¤¤¤ß¼Æ¶q¦h¹è¤§½Õ¾ã À³¬OÂù¤è¬ã¨s«á¨M©w |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/6/12 ¤U¤È 04:34:37
²Ä 5387 ½g¦^À³
|
www.clinicaltrials.gov/ct2/show/NCT03443024
Lebrikizumab 2b ,©Û¶Ò¤¤¤ß¶}58³Bx4组¡A100%¦b¬ü°ê¹Ò¤º¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/6/12 ¤U¤È 04:29:59
²Ä 5386 ½g¦^À³
|
ASLN CEO ¨ü³X¥ç´£¨ì¡A¥»¦¸2bÁ{§É¡A©Û¶Ò¤¤¤ßÀ³¸Ó¥u¦³60³B¡A欧¦{©Û¶Ò¤¤¤ß¡AÀH«á±Nû£°Ê¡A¨Ì¦¹ÁקK«D¶Ç²ÎADªº±wªÌ¡C
5组x59=295 ¤H¡A¤ñ¸û¦X²z¡A
¨º¥Ø«e¤w¶}36³B¡Aªñ60%¡C
¤W¦¸¤¸¤ë¥÷·s»D½Z»¡100Ó©Û¶Ò¤¤¤ß¡A¤Ó¦h¤F¡C
Lebrikizumab 2b ¤]¥u¦³约53³B¡A¥B¬Ò¤j¦h¦b¬ü°ê¹Ò¤º¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/6/12 ¤W¤È 08:16:46
²Ä 5385 ½g¦^À³
|
¨È·à±d¶^ªº¦¹¤w¶^µL¥i¶^¤F ¦A¶^¤]¶È³Ñ¤U¥«¤@³~ ªÑ»ù¦Ü¦¹ §Æ±æ¯à¦b¦¹¥X¶q¿vÓªø©³ µ¥Ô004©Î003ªº¨Îµ
§Ú·|¦b¦¹»ù¦ì¥[½X ¥H¤@³Õ¦ÊªºªÑ»ù ¬°¦ó¤£«÷ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2022/6/11 ¤U¤È 07:40:02
²Ä 5384 ½g¦^À³
|
´Á¤¤¼Æ¾Ú¤£¬O¥²n¡A¦ý«o¬OªÑ»ùªº¶Ê¤Æ¾¯~ |
|
¡@ |
¦^°Q½×°Ï1¶ |
<< 1201 ~ 1300 «h¦^ÂÐ >> |